The Relationship between Leishmaniasis and AIDS: the

Clinical Microbiology Reviews
21, 334-359
DOI: 10.1128/cmr.00061-07

Citation Report

#	Article	IF	Citations
2	Control and prevention of emerging parasitic zoonoses. International Journal for Parasitology, 2008, 38, 1211-1217.	1.3	38
3	Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals. Vaccine, 2008, 26, 5822-5829.	1.7	44
4	Interventions for Old World cutaneous leishmaniasis. The Cochrane Library, 2008, , CD005067.	1.5	106
5	Complexities of Assessing the Disease Burden Attributable to Leishmaniasis. PLoS Neglected Tropical Diseases, 2008, 2, e313.	1.3	295
6	Intracellular Survival ofLeishmaniaSpecies That Cause Visceral Leishmaniasis Is Significantly Reduced by HIVâ€1 Protease Inhibitors. Journal of Infectious Diseases, 2008, 198, 1292-1299.	1.9	64
7	Visceral Leishmaniasis: Advances in Treatment. Recent Patents on Anti-infective Drug Discovery, 2008, 3, 192-198.	0.5	33
8	Bibliography on HIV/AIDS in Ethiopia and Ethiopians in the Diaspora: The 2008 Update. Ethiopian Journal of Health Development, 2009, 23, .	0.2	4
9	HIV Aspartyl Peptidase Inhibitors Interfere with Cellular Proliferation, Ultrastructure and Macrophage Infection of Leishmania amazonensis. PLoS ONE, 2009, 4, e4918.	1.1	66
10	The Antituberculosis Drug Pyrazinamide Affects the Course of Cutaneous Leishmaniasis In Vivo and Increases Activation of Macrophages and Dendritic Cells. Antimicrobial Agents and Chemotherapy, 2009, 53, 5114-5121.	1.4	42
11	Transmission, reservoir hosts and control of zoonotic visceral leishmaniasis. Parasitology, 2009, 136, 1915-1934.	0.7	375
12	Developments in the treatment of visceral leishmaniasis. Expert Opinion on Emerging Drugs, 2009, 14, 395-410.	1.0	79
13	Parasite Susceptibility to Amphotericin B in Failures of Treatment for Visceral Leishmaniasis in Patients Coinfected with HIV Type 1 andLeishmania infantum. Clinical Infectious Diseases, 2009, 48, e16-e22.	2.9	107
14	Arboprotozoae. Transfusion Medicine and Hemotherapy, 2009, 36, 8-31.	0.7	4
15	Neglected Tropical Diseases in Sub-Saharan Africa: Review of Their Prevalence, Distribution, and Disease Burden. PLoS Neglected Tropical Diseases, 2009, 3, e412.	1.3	882
16	Leishmania infantum Amastigotes Enhance HIV-1 Production in Cocultures of Human Dendritic Cells and CD4+ T Cells by Inducing Secretion of IL-6 and TNF-Î±. PLoS Neglected Tropical Diseases, 2009, 3, e441.	1.3	30
17	Neglected tropical diseases in Brazil. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2009, 51, 247-253.	0.5	92
18	Co-Infection of Leishmania (Viannia) braziliensis and HIV: Report of a Case of Mucosal Leishmaniasis in Cochabamba, Bolivia. American Journal of Tropical Medicine and Hygiene, 2009, 81, 555-558.	0.6	11
19	The role of host genetics in leishmaniasis. Trends in Parasitology, 2009, 25, 383-391.	1.5	105

#	Article	IF	Citations
20	Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis. European Journal of Immunology, 2009, 39, 178-191.	1.6	41
22	Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis. Veterinary Parasitology, 2009, 165, 1-18.	0.7	475
23	Synthesis and SAR of alkanediamide-linked bisbenzamidines with anti-trypanosomal and anti-pneumocystis activity. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5884-5886.	1.0	25
24	Amphibian antimicrobial peptides and Protozoa: Lessons from parasites. Biochimica Et Biophysica Acta - Biomembranes, 2009, 1788, 1570-1581.	1.4	89
25	The Chimerical Multi-Component Q protein from Leishmania in the absence of adjuvant protects dogs against an experimental Leishmania infantum infection. Vaccine, 2009, 27, 5964-5973.	1.7	68
26	Tropical dermatology: Tropical diseases caused by protozoa. Journal of the American Academy of Dermatology, 2009, 60, 897-925.	0.6	55
27	Cytokine expression in dogs with naturalLeishmania infantuminfection. Parasitology, 2009, 136, 823-831.	0.7	28
28	Interventions for American cutaneous and mucocutaneous leishmaniasis. The Cochrane Library, 2009, , CD004834.	1.5	114
29	Holiday souvenirs from the Mediterranean: Three instructive cases of visceral leishmaniasis. Scandinavian Journal of Infectious Diseases, 2009, 41, 777-781.	1.5	8
31	COMMUNITY EFFECT OF HAEMOPHILUS INFLUENZAE TYPE B VACCINATION IN INDIA. Pediatric Infectious Disease Journal, 2009, 28, 738-740.	1.1	19
32	APLASTIC ANEMIA FOLLOWING VARICELLA VACCINE. Pediatric Infectious Disease Journal, 2009, 28, 746-748.	1.1	21
33	LONG-TERM LINEZOLID TREATMENT IN A YOUNG CHILD WITH EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS. Pediatric Infectious Disease Journal, 2009, 28, 748-750.	1.1	45
34	A VERY RARE CAUSE OF CHILDHOOD PARAPARESIS. Pediatric Infectious Disease Journal, 2009, 28, 754-755.	1.1	18
35	ILEOCECAL HISTOPLASMOSIS SIMULATING CROHN DISEASE IN A PATIENT WITH HYPERIMMUNOGLOBULIN E SYNDROME. Pediatric Infectious Disease Journal, 2009, 28, 744-746.	1.1	26
36	VISCERAL LEISHMANIASIS ASSOCIATED HEMOPHAGOCYTIC SYNDROME IN PATIENTS WITH CHRONIC GRANULOMATOUS DISEASE. Pediatric Infectious Disease Journal, 2009, 28, 753-754.	1.1	32
37	A PROSPECTIVE MULTICENTER STUDY OF CHILDHOOD ENCEPHALITIS IN GREECE. Pediatric Infectious Disease Journal, 2009, 28, 740-742.	1.1	21
38	SEVERE CLOSTRIDIUM DIFFICILE COLITIS AND REACTIVE ARTHRITIS IN A TEN-YEAR-OLD CHILD. Pediatric Infectious Disease Journal, 2009, 28, 750-751.	1.1	16
39	RENAL AND MILIARY TUBERCULOSIS IN AN INTERNATIONALLY ADOPTED INFANT. Pediatric Infectious Disease Journal, 2009, 28, 751-753.	1.1	5

#	Article	IF	Citations
40	ASSOCIATION OF STAPHYLOCOCCUS AUREUS COLONIZATION IN PARTURIENT MOTHERS AND THEIR BABIES. Pediatric Infectious Disease Journal, 2009, 28, 742-744.	1.1	32
43	Unique Aspects of the Care of HIV-Positive Latino Patients Living in the United States. Current HIV/AIDS Reports, 2010, 7, 107-116.	1.1	11
44	Effects of HIV aspartyl-proteinase inhibitors on Leishmania sp.. Experimental Parasitology, 2010, 126, 557-563.	0.5	39
45	Clinical risk factors for therapeutic failure in kala-azar patients treated with pentavalent antimonials in Nepal. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2010, 104, 225-229.	0.7	24
46	In vitro and in vivo anti-Leishmania activity of polysubstituted synthetic chalcones. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 100-103.	1.0	59
47	High levels of T lymphocyte activation in Leishmania-HIV-1 co-infected individuals despite low HIV viral load. BMC Infectious Diseases, 2010, 10, 358.	1.3	40
48	Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV coâ€infection in northwest Ethiopia. Tropical Medicine and International Health, 2010, 15, 848-855.	1.0	84
49	Leishmaniacell surface prohibitin: role in host-parasite interaction. Cellular Microbiology, 2010, 12, 432-452.	1.1	34
50	Visceral leishmaniasis due to Leishmania donovani in a patient with advanced HIV infection. Medical Journal of Australia, 2010, 192, 474-475.	0.8	2
51	HIV/AIDS-associated visceral leishmaniasis in patients from an endemic area in Central-west Brazil. Memorias Do Instituto Oswaldo Cruz, 2010, 105, 692-697.	0.8	35
52	Visceral Leishmaniasis Treated with Antimonials/Paromomycin followed by Itraconazole/Miltefosine after Standard Therapy Failures in a Human Immunodeficiency Virusâ€"Infected Patient. American Journal of Tropical Medicine and Hygiene, 2010, 83, 10-12.	0.6	29
53	Importance of Nonenteric Protozoan Infections in Immunocompromised People. Clinical Microbiology Reviews, 2010, 23, 795-836.	5.7	89
54	Once bitten, twice shy. Thorax, 2010, 65, 56-56.	2.7	0
55	The biology and control of leishmaniasis vectors. Journal of Global Infectious Diseases, 2010, 2, 127.	0.2	57
56	Drug Resistance in Visceral Leishmaniasis. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-8.	3.0	158
57	Nelfinavir, an HIV-1 Protease Inhibitor, Induces Oxidative Stressâ€"Mediated, Caspase-Independent Apoptosis in Leishmania Amastigotes. PLoS Neglected Tropical Diseases, 2010, 4, e642.	1.3	34
58	Expansion of the target of rapamycin (TOR) kinase family and function in Leishmania shows that TOR3 is required for acidocalcisome biogenesis and animal infectivity. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 11965-11970.	3.3	78
59	Upper airway. 3: Sinonasal involvement in chronic obstructive pulmonary disease. Thorax, 2010, 65, 85-90.	2.7	38

#	Article	IF	Citations
60	Immunological perspectives of leishmaniasis. Journal of Global Infectious Diseases, 2010, 2, 135.	0.2	148
61	Pediatric Visceral Leishmaniasis in Albania: A Retrospective Analysis of 1,210 Consecutive Hospitalized Patients (1995â€“2009). PLoS Neglected Tropical Diseases, 2010, 4, e814.	1.3	45
62	Risk Factors for Anthroponotic Cutaneous Leishmaniasis at the Household Level in Kabul, Afghanistan. PLoS Neglected Tropical Diseases, 2010, 4, e639.	1.3	60
63	Of Cattle, Sand Flies and Men: A Systematic Review of Risk Factor Analyses for South Asian Visceral Leishmaniasis and Implications for Elimination. PLoS Neglected Tropical Diseases, 2010, 4, e599.	1.3	115
65	Human leishmaniasis in Tuscany: a changing pattern of visceral disease?. Annals of Tropical Medicine and Parasitology, 2010, 104, 171-174.	1.6	3
66	Trypanosomatid Parasites Causing Neglected Diseases. Current Medicinal Chemistry, 2010, 17, 1594-1617.	1.2	89
67	Asymptomatic Leishmania infantum Infection in an Area of Northwestern Italy (Piedmont) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 48, 131-136.	1.8	91
68	Current diagnosis and treatment of visceral leishmaniasis. Expert Review of Anti-Infective Therapy, 2010, 8, 919-944.	2.0	79
69	Scientometric analysis of the world-wide research efforts concerning Leishmaniasis. Parasites and Vectors, 2010, 3, 14.	1.0	19
70	Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Review of Anti-Infective Therapy, 2010, 8, 419-433.	2.0	363
71	A plate-based assay system for analyses and screening of the Leishmania major inositol phosphorylceramide synthase. International Journal of Biochemistry and Cell Biology, 2010, 42, 1553-1561.	1.2	25
72	Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure â€” a case report and brief review of the literature. International Journal of Infectious Diseases, 2010, 14, e522-e525.	1.5	33
73	Leishmaniasis, an emerging infection in travelers. International Journal of Infectious Diseases, 2010, 14, e1032-e1039.	1.5	139
74	Infecciones por protozoos hemoflagelados I: leishmaniosis. Medicine, 2010, 10, 3621-3631.	0.0	1
75	Combination therapy for visceral leishmaniasis. Lancet Infectious Diseases, The, 2010, 10, 184-194.	4.6	268
76	Vaccination with Recombinant Leishmania donovani Gamma-Glutamylcysteine Synthetase Fusion Protein Protects Against L. donovani Infection. Journal of Parasitology, 2010, 96, 929-936.	0.3	12
78	A Serological and Molecular Study ofLeishmania infantumInfection in Cats from the Island of Ibiza (Spain). Vector-Borne and Zoonotic Diseases, 2011, 11, 239-245.	0.6	64
79	Importance of worldwide asymptomatic carriers of Leishmania infantum (L. chagasi) in human. Acta Tropica, 2011, 119, 69-75.	0.9	173

#	Article	IF	Citations
80	Exploring Leishmania major Inositol Phosphorylceramide Synthase (LmjIPCS): Insights into the ceramide binding domain. Organic and Biomolecular Chemistry, 2011, 9, 1823.	1.5	31
82	Enlarging the â€œAudacious Goalâ€: Elimination of the world's high prevalence neglected tropical diseases. Vaccine, 2011, 29, D104-D110.	1.7	65
84	Immunophenotyping of circulating T cells in a mucosal leishmaniasis patient coinfected with HIV. Revista Da Sociedade Brasileira De Medicina Tropical, 2011, 44, 520-521.	0.4	6
85	An experimental protocol for the establishment of dogs with long-term cellular immune reactions to Leishmania antigens. Memorias Do Instituto Oswaldo Cruz, 2011, 106, 182-189.	0.8	12
86	Leishmaniases. , 2011, , 453-480.		11
87	Evaluation of HIV-Leishmania co-infection in patients from the northwestern ParanÃ¡ State, Brazil. Acta Scientiarum - Health Sciences, 2011, 33, .	0.2	1
88	Methods of Control of theLeishmania infantumDog Reservoir: State of the Art. Veterinary Medicine International, 2011, 2011, 1-13.	0.6	32
89	Predictors of Visceral Leishmaniasis Relapse in HIV-Infected Patients: A Systematic Review. PLoS Neglected Tropical Diseases, 2011, 5, e1153.	1.3	137
90	Multi-Target-Directed Ligands as Innovative Tools to Combat Trypanosomatid Diseases. Current Topics in Medicinal Chemistry, 2011, 11, 2824-2833.	1.0	14
91	Intracellular Protozoan Parasites of Humans: The Role of Molecular Chaperones in Development and Pathogenesis. Protein and Peptide Letters, 2011, 18, 143-157.	0.4	115
92	SIV infection of rhesus macaques results in dysfunctional T- and B-cell responses to neo and recall Leishmania major vaccination. Blood, 2011, 118, 5803-5812.	0.6	45
93	Visceral Leishmaniasis Mimicking as Second Line Anti Retroviral Therapy Failure. Internal Medicine, 2011, 50, 2855-2858.	0.3	6
94	Recurrent leishmaniasis in kidney transplant recipients: report of 2 cases and systematic review of the literature. Transplant Infectious Disease, 2011, 13, 397-406.	0.7	49
95	Transfusionâ€transmitted visceral leishmaniasis caused by Leishmania (Leishmania) mexicana in an immunocompromised patient: a case report. Transfusion, 2011, 51, 1919-1923.	0.8	25
96	Leishmaniasis chemotherapyâ€”challenges and opportunities. Clinical Microbiology and Infection, 2011, 17, 1478-1483.	2.8	353
97	Leishmaniasis impact and treatment access. Clinical Microbiology and Infection, 2011, 17, 1471-1477.	2.8	204
98	Clinical pleiomorphism in human leishmaniases, with special mention of asymptomatic infection. Clinical Microbiology and Infection, 2011, 17, 1451-1461.	2.8	101
99	The nature and consequences of coinfection in humans. Journal of Infection, 2011, 63, 200-206.	1.7	190

#	Article	IF	Citations
100	Therapeutic Potential of Phosphodiesterase Inhibitors in Parasitic Diseases. Handbook of Experimental Pharmacology, 2011, , 487-510.	0.9	30
101	A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy. International Journal of Clinical Pharmacy, 2011, 33, 726-729.	1.0	13
102	The prevalence of canine Leishmania infantum infection in Sichuan Province, southwestern China detected by real time PCR. Parasites and Vectors, 2011, 4, 173.	1.0	20
103	LeishVet guidelines for the practical management of canine leishmaniosis. Parasites and Vectors, 2011, 4, 86.	1.0	533
104	New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas. Drug Development Research, 2011, 72, 451-462.	1.4	3
105	HIV-1 does not significantly influence Chlamydia trachomatis serovar L2 replication in vitro. Microbes and Infection, 2011, 13, 575-584.	1.0	4
106	Seroprevalence of Leishmania infantum in a rural area of Senegal: analysis of risk factors involved in transmission to humans. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2011, 105, 333-340.	0.7	23
108	Disseminated Cutaneous Leishmaniasis Resembling Post-Kala-Azar Dermal Leishmaniasis Caused by Leishmania donovani in Three Patients Co-Infected with Visceral Leishmaniasis and Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome in Ethiopia. American Journal of Tropical Medicine and Hygiene, 2011, 84, 906-912.	0.6	25
109	A Patient Presenting with Diffuse Cutaneous Leishmaniasis (DCL) as a First Indicator of HIV Infection in India. American Journal of Tropical Medicine and Hygiene, 2011, 85, 64-65.	0.6	18
110	American Tegumentary Leishmaniasis and HIV-AIDS Association in a Tertiary Care Center in the Brazilian Amazon. American Journal of Tropical Medicine and Hygiene, 2011, 85, 524-527.	0.6	35
111	Liposomal Amphotericin B for Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients: 2-Year Treatment Outcomes in Bihar, India. Clinical Infectious Diseases, 2011, 53, e91-e98.	2.9	74
112	Paf-Metabolic Enzymes and Paf-like Activity in L. Infantum and L. Major Promastigotes. European Journal of Inflammation, 2011, 9, 231-239.	0.2	7
113	Atypical Presentation of Visceral Leishmaniasis in a HIV-positive Patient from a Nonendemic Area. Journal of Laboratory Physicians, 2011, 3, 119-121.	0.4	3
114	Enhancement of Experimental Cutaneous Leishmaniasis byLeishmaniaMolecules Is Dependent on Interleukin-4, Serine Protease/Esterase Activity, and Parasite and Host Genetic Backgrounds. Infection and Immunity, 2011, 79, 1236-1243.	1.0	9
115	Comparison of Insecticide-Treated Nets and Indoor Residual Spraying to Control the Vector of Visceral Leishmaniasis in Mymensingh District, Bangladesh. American Journal of Tropical Medicine and Hygiene, 2011, 84, 662-667.	0.6	31
116	Th1/Th2 Cytokine Profile in Patients Coinfected with HIV and Leishmania in Brazil. Vaccine Journal, 2011, 18, 1765-1769.	3.2	13
117	Prevalence ofStrongyloides stercoralisinfection among HIV-positive immigrants attending two Italian hospitals, from 2000 to 2009. Annals of Tropical Medicine and Parasitology, 2011, 105, 617-623.	1.6	40
118	Visceral Leishmaniasis in a Child Infected with the Human Immunodeficiency Virus in a Non-endemic Region. Journal of Tropical Pediatrics, 2011, 57, 493-495.	0.7	3

#	Article	IF	Citations
119	Therapy of vector-borne protozoan infections in nonendemic settings. Expert Review of Anti-Infective Therapy, 2011, 9, 583-608.	2.0	3
120	Epidemiology of Leishmaniasis in Spain Based on Hospitalization Records (1997â€“2008). American Journal of Tropical Medicine and Hygiene, 2011, 85, 820-825.	0.6	37
121	Drug susceptibility of Leishmania infantum (syn. Leishmania chagasi) isolates from Brazilian HIV-positive and HIV-negative patients. Journal of Antimicrobial Chemotherapy, 2011, 66, 677-679.	1.3	10
122	Linezolid for endocarditis: a case series of 14 patients. Journal of Antimicrobial Chemotherapy, 2011, 66, 679-682.	1.3	24
123	Linking Global HIV/AIDS Treatments with National Programs for the Control and Elimination of the Neglected Tropical Diseases. PLoS Neglected Tropical Diseases, 2011, 5, e1022.	1.3	14
124	Visceral Leishmaniasis with Endobronchial Involvement in an Immunocompetent Adult. Case Reports in Medicine, 2011, 2011, 1-5.	0.3	11
125	The Neglected Tropical Diseases of India and South Asia: Review of Their Prevalence, Distribution, and Control or Elimination. PLoS Neglected Tropical Diseases, 2011, 5, e1222.	1.3	56
126	Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial. PLoS Neglected Tropical Diseases, 2012, 6, e1674.	1.3	123
127	Heme Uptake by Leishmania amazonensis Is Mediated by the Transmembrane Protein LHR1. PLoS Pathogens, 2012, 8, e1002795.	2.1	88
128	The Diagnostic Accuracy of Serologic and Molecular Methods for Detecting Visceral Leishmaniasis in HIV Infected Patients: Meta-Analysis. PLoS Neglected Tropical Diseases, 2012, 6, e1665.	1.3	117
129	In Vitro and In Vivo Efficacy of Ether Lipid Edelfosine against Leishmania spp. and SbV-Resistant Parasites. PLoS Neglected Tropical Diseases, 2012, 6, e1612.	1.3	46
130	Heterogeneity of Environments Associated with Transmission of Visceral Leishmaniasis in South-Eastern France and Implication for Control Strategies. PLoS Neglected Tropical Diseases, 2012, 6, e1765.	1.3	17
131	Leishmania Induces Survival, Proliferation and Elevated Cellular dNTP Levels in Human Monocytes Promoting Acceleration of HIV Co-Infection. PLoS Pathogens, 2012, 8, e1002635.	2.1	46
133	Usefulness of the rK39-Immunochromatographic Test, Direct Agglutination Test, and Leishmanin Skin Test for Detecting Asymptomatic Leishmania Infection in Children in a New Visceral Leishmaniasis Focus in Amhara State, Ethiopia. American Journal of Tropical Medicine and Hygiene, 2012, 86, 792-798.	0.6	36
134	Consecutive Cutaneous and Visceral Leishmaniasis Manifestations Involving a Novel Leishmania Species in Two HIV Patients in Thailand. American Journal of Tropical Medicine and Hygiene, 2012, 87, 76-80.	0.6	37
135	Mechanisms of interaction between protozoan parasites and HIV. Current Opinion in HIV and AIDS, 2012, 7, 275-281.	1.5	30
136	Recent advances in development of amphotericin B formulations for the treatment of visceral leishmaniasis. Current Opinion in Infectious Diseases, 2012, 25, 695-702.	1.3	31
137	Innovative Lead Compounds and Formulation Strategies As Newer Kinetoplastid Therapies. Current Medicinal Chemistry, 2012, 19, 4259-4288.	1.2	42

#	Article	IF	Citations
138	Leishmaniasis: Prevention, Parasite Detection and Treatment. Current Medicinal Chemistry, 2012, 19, 1443-1474.	1.2	97
139	Identification and Diagnostic Utility of Leishmania infantum Proteins Found in Urine Samples from Patients with Visceral Leishmaniasis. Vaccine Journal, 2012, 19, 935-943.	3.2	25
140	Autochthonous Disseminated Dermal and Visceral Leishmaniasis in an AIDS Patient, Southern Thailand, Caused by Leishmania siamensis. American Journal of Tropical Medicine and Hygiene, 2012, 86, 821-824.	0.6	58
141	Dolabelladienetriol, a Compound from Dictyota pfaffii Algae, Inhibits the Infection by Leishmania amazonensis. PLoS Neglected Tropical Diseases, 2012, 6, e1787.	1.3	42
142	Aurones: A Promising Heterocyclic Scaffold for the Development of Potent Antileishmanial Agents. International Journal of Medicinal Chemistry, 2012, 2012, 1-8.	2.2	27
143	Lipopolysaccharide-Induced Cellular Activation May Participate in the Immunopathogenesis of Visceral Leishmaniasis Alone or in HIV Coinfection. International Journal of Microbiology, 2012, 2012, 1-4.	0.9	7
144	Developments in Diagnosis and Antileishmanial Drugs. Interdisciplinary Perspectives on Infectious Diseases, 2012, 2012, 1-13.	0.6	47
145	Leishmaniasis in the United States: Treatment in 2012. American Journal of Tropical Medicine and Hygiene, 2012, 86, 434-440.	0.6	59
146	Leishmaniasis in rheumatology, haematology and oncology: epidemiological, immunological and clinical aspects and caveats: Figure 1. Annals of the Rheumatic Diseases, 2012, 71, i60-i66.	0.5	71
147	Management of trypanosomiasis and leishmaniasis. British Medical Bulletin, 2012, 104, 175-196.	2.7	240
148	Infections and inequalities: anemia in AIDS, the disadvantages of poverty. Asian Pacific Journal of Tropical Biomedicine, 2012, 2, 485-488.	0.5	5
149	Immunopathogenesis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis. Seminars in Immunopathology, 2012, 34, 735-751.	2.8	102
150	Previous exposure to a low infectious dose of Leishmania major exacerbates infection with Leishmania infantum in the susceptible BALB/c mouse. Parasitology Research, 2012, 111, 1407-1415.	0.6	10
151	Genetic polymorphism in Leishmania (Viannia) braziliensis detected in mucosal leishmaniasis of HIV-infected and non-HIV-infected patients. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2012, 106, 683-687.	0.7	5
152	Miltefosine represses HIV-1 replication in human dendritic cell/T-cell cocultures partially by inducing secretion of type-I interferon. Virology, 2012, 432, 271-276.	1.1	9
153	Expression of infection-related genes in parasites and host during murine experimental infection with Leishmania (Leishmania) amazonensis. Microbial Pathogenesis, 2012, 52, 101-108.	1.3	10
155	Synthesis and Structureâ€"Activity Relationships of Lansine Analogues as Antileishmanial Agents. ChemMedChem, 2012, 7, 1895-1900.	1.6	15
156	<scp>TLR</scp>â€mediated distinct <scp>IFN</scp>â€Î³/<scp>IL</scp>â€10 pattern induces protective immunity against murine visceral leishmaniasis. European Journal of Immunology, 2012, 42, 2087-2099.	1.6	32

#	Article	IF	Citations
157	The burden of neglected tropical diseases in Ethiopia, and opportunities for integrated control and elimination. Parasites and Vectors, 2012, 5, 240.	1.0	152
158	Antileishmanial Natural Products from Plants. Studies in Natural Products Chemistry, 2012, , 331-382.	0.8	18
159	Formulation of oryzalin (ORZ) liposomes: In vitro studies and in vivo fate. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 82, 281-290.	2.0	16
160	Visceral Leishmaniasis. Infectious Disease Clinics of North America, 2012, 26, 309-322.	1.9	217
161	Peptidomimetic and Organometallic Derivatives of Primaquine Active against Leishmania infantum. Antimicrobial Agents and Chemotherapy, 2012, 56, 5774-5781.	1.4	30
162	Cutaneous and Mucocutaneous Leishmaniasis. Infectious Disease Clinics of North America, 2012, 26, 293-307.	1.9	129
163	HIV-1 Promotes Intake of Leishmania Parasites by Enhancing Phosphatidylserine-Mediated, CD91/LRP-1-Dependent Phagocytosis in Human Macrophages. PLoS ONE, 2012, 7, e32761.	1.1	23
164	Vaccines for Canine Leishmaniasis. Frontiers in Immunology, 2012, 3, 69.	2.2	66
165	Diagnosing visceral leishmaniasis and HIV/AIDS co-infection: a case series study in Pernambuco, Brazil. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2012, 54, 43-47.	0.5	16
166	Slow clinical improvement after treatment initiation in Leishmania/HIV coinfected patients. Revista Da Sociedade Brasileira De Medicina Tropical, 2012, 45, 147-150.	0.4	18
167	Review of the current treatments for leishmaniases. Research and Reports in Tropical Medicine, 2012, 3, 69.	2.8	34
168	Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems. Expert Review of Vaccines, 2012, 11, 69-86.	2.0	22
169	Visceral leishmaniasis in a patient with AIDS: early pathological diagnosis using conventional histology, PCR and electron microscopy is the key for adequate treatment. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 357-360.	1.4	5
170	Significance of persistence of antibodies against Leishmania infantum in sicilian patients affected by acute visceral leishmaniasis. Clinical and Experimental Medicine, 2012, 12, 127-132.	1.9	6
171	Cloning, overexpression and characterization of Leishmania donovani triosephosphate isomerase. Experimental Parasitology, 2012, 130, 430-436.	0.5	14
172	Role of trypanosomatid's arginase in polyamine biosynthesis and pathogenesis. Molecular and Biochemical Parasitology, 2012, 181, 85-93.	0.5	49
173	Characterization of Leishmania infantum thiolâ€dependent reductase 1 and evaluation of its potential to induce immune protection. Parasite Immunology, 2012, 34, 345-350.	0.7	14
174	Leishmaniasis: new insights from an old and neglected disease. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 109-118.	1.3	94

#	Article	IF	Citations
175	Detection of Leishmania donovani infection using magnetic beads-based serum peptide profiling by MALDI-TOF MS in mice model. Parasitology Research, 2012, 110, 1287-1290.	0.6	9
176	Characterization of the biology and infectivity of Leishmania infantum viscerotropic and dermotropic strains isolated from HIV+ and HIV- patients in the murine model of visceral leishmaniasis. Parasites and Vectors, 2013, 6, 122.	1.0	40
177	T and B lymphocytes in the brains of dogs with concomitant seropositivity to three pathogenic protozoans: Leishmania chagasi, Toxoplasma gondii and Neospora caninum. BMC Research Notes, 2013, 6, 226.	0.6	10
178	Recurrent visceral leishmaniasis in an immunocompetent patient: a case report. Journal of Medical Case Reports, 2013, 7, 68.	0.4	6
179	Visceral leishmaniasis revealed by a squamous cell carcinoma in an HIV-1 infected patient. Infection, 2013, 41, 575-578.	2.3	6
180	Gene expression modulation and the molecular mechanisms involved in <scp>N</scp>elfinavir resistance in <scp>L</scp>eishmania donovani axenic amastigotes. Molecular Microbiology, 2013, 89, 565-582.	1.2	15
181	The immunology of Leishmania/HIV co-infection. Immunologic Research, 2013, 56, 163-171.	1.3	73
183	Strategies for the design of orally bioavailable antileishmanial treatments. International Journal of Pharmaceutics, 2013, 454, 539-552.	2.6	50
184	Drug Resistance in Leishmania Parasites. , 2013, , .		13
185	Evaluation of PCR procedures for detecting and quantifying Leishmania donovani DNA in large numbers of dried human blood samples from a visceral leishmaniasis focus in Northern Ethiopia. BMC Infectious Diseases, 2013, 13, 153.	1.3	52
186	Synthesis and antiprotozoal activities of benzyl phenyl ether diamidine derivatives. European Journal of Medicinal Chemistry, 2013, 67, 310-324.	2.6	21
187	In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs. Experimental Parasitology, 2013, 135, 36-41.	0.5	35
188	Novel therapeutic strategies for treatment of visceral leishmaniasis. Drug Discovery Today, 2013, 18, 1272-1281.	3.2	73
189	Microbial Translocation Induces an Intense Proinflammatory Response in Patients With Visceral Leishmaniasis and HIV Type 1 Coinfection. Journal of Infectious Diseases, 2013, 208, 57-66.	1.9	42
190	HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals. Lancet Infectious Diseases, The, 2013, 13, 251-259.	4.6	39
191	Human visceral leishmaniasis: A picture from Italy. Journal of Infection and Public Health, 2013, 6, 465-472.	1.9	9
192	Therapeutic Options for Visceral Leishmaniasis. Drugs, 2013, 73, 1863-1888.	4.9	73
193	Cationic solidâ€“lipid nanoparticles are as efficient as electroporation in <scp>DNA</scp> vaccination against visceral leishmaniasis in mice. Parasite Immunology, 2013, 35, 397-408.	0.7	41

#	Article	IF	Citations
194	Immunodiagnosis of CNS parasitic infections. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 114, 23-36.	1.0	8
195	Bibliometric analysis of leishmaniasis research in Medline (1945-2010). Parasites and Vectors, 2013, 6, 55.	1.0	49
196	Postâ€kalaâ€azar dermal leishmaniasis in <scp>HIV</scp>â€infected patients with <scp>AIDS</scp>: a report of two cases diagnosed in the <scp>USA</scp>. International Journal of Dermatology, 2013, 52, 1098-1104.	0.5	6
197	Drug-resistant microorganisms with a higher fitness â€“ can medicines boost pathogens?. Critical Reviews in Microbiology, 2013, 39, 384-394.	2.7	33
198	Leishmaniasis: an update of current pharmacotherapy. Expert Opinion on Pharmacotherapy, 2013, 14, 53-63.	0.9	207
200	Phlebotomine sandflies and the spreading of leishmaniases and other diseases of public health concern. Medical and Veterinary Entomology, 2013, 27, 123-147.	0.7	550
201	The Concept of Fitness and Drug Resistance in Leishmania. , 2013, , 431-449.		5
202	Parasitic Kidney Disease: Milestones in the Evolution of Our Knowledge. American Journal of Kidney Diseases, 2013, 61, 501-513.	2.1	10
203	Two cases of successful treatment of multilesional cutaneous leishmaniasis with liposomal amphotericin B. JDDG - Journal of the German Society of Dermatology, 2013, 11, 83-85.	0.4	4
204	Erfolgreiche Behandlung von zwei Patienten mit multilÃsionaler kutaner Leishmaniasis mit liposomalem Amphotericin. JDDG - Journal of the German Society of Dermatology, 2013, 11, 83-85.	0.4	2
206	Human hepatic stellate cells in primary culture are safe targets forLeishmania donovani. Parasitology, 2013, 140, 471-481.	0.7	3
207	An Unwelcome Synergy: Leishmaniasis and HIV. American Journal of Medicine, 2013, 126, 114-116.	0.6	0
208	Mechanisms of Miltefosine Resistance in Leishmania. , 2013, , 351-379.		3
209	Drug Targets, Drug Effectors, and Drug Targeting and Delivery. , 2013, , 321-350.		0
210	Epidemiology of Leishmaniasis in the Time of Drug Resistance. , 2013, , 65-83.		4
211	Co-infection with HIV. , 2013, , 167-181.		1
212	Visceral Leishmaniasis. , 2013, , 183-198.		2
213	Introduction: Leishmaniasis â€“ The Biology of a Parasite. , 2013, , 1-12.		1

#	Article	IF	Citations
214	Synthesis and Antiprotozoal Activity of Dicationic m-Terphenyl and 1,3-Dipyridylbenzene Derivatives. Journal of Medicinal Chemistry, 2013, 56, 5473-5494.	2.9	35
215	The therapeutic potential of immune cross-talk in leishmaniasis. Clinical Microbiology and Infection, 2013, 19, 119-130.	2.8	27
216	Seroprevalence and asymptomatic carriage of Leishmania spp. in Austria, a non-endemic European country. Clinical Microbiology and Infection, 2013, 19, 572-577.	2.8	15
217	RELAPSING VISCERAL LEISHMANIASIS IN A HIV-1 INFECTED PATIENT WITH ADVANCED DISEASE. Acta Clinica Belgica, 2013, 68, 124-127.	0.5	1
219	Efficacy of Anti-Leishmania Therapy in Visceral Leishmaniasis among HIV Infected Patients: A Systematic Review with Indirect Comparison. PLoS Neglected Tropical Diseases, 2013, 7, e2195.	1.3	171
220	Validation of Two Rapid Diagnostic Tests for Visceral Leishmaniasis in Kenya. PLoS Neglected Tropical Diseases, 2013, 7, e2441.	1.3	13
221	Indoleamine 2,3-dioxygenase activity as a potential biomarker of immune suppression during visceral leishmaniasis. Innate Immunity, 2013, 19, 564-568.	1.1	15
222	Arginase Activity in the Blood of Patients with Visceral Leishmaniasis and HIV Infection. PLoS Neglected Tropical Diseases, 2013, 7, e1977.	1.3	48
223	Mucosal Leishmaniasis: An Underestimated Presentation of a Neglected Disease. BioMed Research International, 2013, 2013, 1-7.	0.9	89
224	Clinical aspects of visceral leishmaniasis in HIV infection. Current Opinion in Infectious Diseases, 2013, 26, 1-9.	1.3	81
225	Nelfinavir is effective in inhibiting the multiplication and aspartic peptidase activity of Leishmania species, including strains obtained from HIV-positive patients. Journal of Antimicrobial Chemotherapy, 2013, 68, 348-353.	1.3	31
226	What steps can be taken to counter the increasing failure of miltefosine to treat visceral leishmaniasis?. Expert Review of Anti-Infective Therapy, 2013, 11, 117-119.	2.0	13
227	Challenges in the Therapy of Visceral Leishmaniasis in Brazil: A Public Health Perspective. Journal of Tropical Medicine, 2013, 2013, 1-5.	0.6	15
228	Ultrasensitive Real-Time PCR for the Clinical Management of Visceral Leishmaniasis in HIV-Infected Patients. American Journal of Tropical Medicine and Hygiene, 2013, 89, 105-110.	0.6	36
229	Intermediate/borderline disseminated cutaneous leishmaniasis. International Journal of Dermatology, 2013, 52, 446-455.	0.5	17
230	Postâ€Kalaâ€azar dermal leishmaniasis due to Leishmania donovani in Europe â€“ Case report. International Journal of Dermatology, 2013, 52, 1584-1586.	0.5	1
231	Tropical Diseases Screening in Immigrant Patients with Human Immunodeficiency Virus Infection in Spain. American Journal of Tropical Medicine and Hygiene, 2013, 88, 1196-1202.	0.6	45
232	Comparison of Parasitological, Serological, and Molecular Tests for Visceral Leishmaniasis in HIV-Infected Patients: A Cross-Sectional Delayed-Type Study. American Journal of Tropical Medicine and Hygiene, 2013, 89, 570-577.	0.6	58

#	Article	IF	Citations
233	Letter to the Editor A rare case of dysphagia in a severely immunocompromised patient. Archives of Medical Science, 2013, 2, 381-383.	0.4	0
234	Human immunodeficiency virus/Leishmania infantum in the first foci of urban American visceral leishmaniasis: clinical presentation from 1994 to 2010. Revista Da Sociedade Brasileira De Medicina Tropical, 2013, 46, 156-160.	0.4	21
235	USEFULNESS OF kDNA PCR IN THE DIAGNOSIS OF VISCERAL LEISHMANIASIS REACTIVATION IN CO-INFECTED PATIENTS. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2013, 55, 429-431.	0.5	8
236	Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence. Revista Da Sociedade Brasileira De Medicina Tropical, 2013, 46, 669-677.	0.4	27
237	Aspartic Peptidases of Human Pathogenic Trypanosomatids: Perspectives and Trends for Chemotherapy. Current Medicinal Chemistry, 2013, 20, 3116-3133.	1.2	33
239	Synthesis of simple molecules prepared as arginase inhibitors and evaluated against Leishmania amazonensis. Journal of Microbiology and Antimicrobials, 2013, 5, 72-86.	0.3	2
241	Trypanosomatid Aquaporins: Roles in Physiology and Drug Response. Diseases (Basel, Switzerland), 2014, 2, 3-23.	1.0	9
242	Can Attenuated Leishmania Induce Equally Effective Protection as Virulent Strains in Visceral Leishmaniasis?. , 2014, , .		0
243	HIV/AIDS-related visceral leishmaniasis: a clinical and epidemiological description of visceral leishmaniasis in northern Brazil. Revista Da Sociedade Brasileira De Medicina Tropical, 2014, 47, 38-46.	0.4	26
244	Complementary exams in the diagnosis of american tegumentary leishmaniasis. Anais Brasileiros De Dermatologia, 2014, 89, 701-709.	0.5	54
245	Effect of Amphotericin B Nanodisks on Leishmania major Infected Mice. Pharmaceutica Analytica Acta, 2014, 05, .	0.2	8
246	Clinical Features and Management of HIV/AIDS. , 2014, , 79-96.e6.		3
247	Leishmaniases. , 2014, , .		1
248	Influence of Human Leukocyte Antigen on Susceptibility of Tropical Pulmonary Infectious Diseases and Clinical Implications. , 2014, , .		0
249	Data collection to characterise the impact of canine leishmaniosis and modelling of the role of animals in spreading Leishmania infantum within the European Union. EFSA Supporting Publications, 2014, 11, 466E.	0.3	1
250	Trypanosomatids topoisomerase re-visited. New structural findings and role in drug discovery. International Journal for Parasitology: Drugs and Drug Resistance, 2014, 4, 326-337.	1.4	39
252	Visceral leishmaniasis due to Leishmania infantumwith renal involvement in HIV-infected patients. BMC Infectious Diseases, 2014, 14, 561.	1.3	10
253	Editorial Commentary: Visceral Leishmaniasis and HIV Coinfection in Bihar, India: A Wake-up Call?. Clinical Infectious Diseases, 2014, 59, 556-558.	2.9	7

#	Article	IF	Citations
254	Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India. PLoS Neglected Tropical Diseases, 2014, 8, e2603.	1.3	52
255	Visceral Leishmaniasis and HIV Coinfection in East Africa. PLoS Neglected Tropical Diseases, 2014, 8, e2869.	1.3	114
256	Visceral Leishmaniasis and HIV Coinfection in the Mediterranean Region. PLoS Neglected Tropical Diseases, 2014, 8, e3021.	1.3	99
257	Epidemiological patterns of mortality due to visceral leishmaniasis and HIV/AIDS co-infection in Brazil, 2000â€“2011. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2014, 108, 338-347.	0.7	20
258	Drug Resistance in Leishmania. , 2014, , 1-24.		4
259	Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India. PLoS Neglected Tropical Diseases, 2014, 8, e2536.	1.3	49
260	Visceral Leishmaniasis in Ethiopia: An Evolving Disease. PLoS Neglected Tropical Diseases, 2014, 8, e3131.	1.3	87
261	Species-Directed Therapy for Leishmaniasis in Returning Travellers: A Comprehensive Guide. PLoS Neglected Tropical Diseases, 2014, 8, e2832.	1.3	74
262	Visceral leishmaniasis mimicking Richter transformation. Leukemia and Lymphoma, 2014, 55, 2952-2954.	0.6	4
263	Epidemiology of Visceral Leishmaniasis in Georgia. PLoS Neglected Tropical Diseases, 2014, 8, e2725.	1.3	32
264	Risk Factors for Adverse Prognosis and Death in American Visceral Leishmaniasis: A Meta-analysis. PLoS Neglected Tropical Diseases, 2014, 8, e2982.	1.3	74
265	Leishmania aethiopica Field Isolates Bearing an Endosymbiontic dsRNA Virus Induce Pro-inflammatory Cytokine Response. PLoS Neglected Tropical Diseases, 2014, 8, e2836.	1.3	79
266	Visceral Leishmaniasis Relapse in HIV Patientsâ€”A Role for Myeloid-Derived Suppressor Cells?. PLoS Neglected Tropical Diseases, 2014, 8, e3132.	1.3	3
267	Knowledge and Use of Emergency Contraception: A Multicountry Analysis. International Perspectives on Sexual and Reproductive Health, 2014, 40, 079-086.	3.8	23
268	Visceral Leishmaniasis and HIV Coinfection in Latin America. PLoS Neglected Tropical Diseases, 2014, 8, e3136.	1.3	88
269	Leishmania-HIV Co-infection: Clinical Presentation and Outcomes in an Urban Area in Brazil. PLoS Neglected Tropical Diseases, 2014, 8, e2816.	1.3	67
270	Prognostic Factors and Scoring System for Death from Visceral Leishmaniasis: An Historical Cohort Study in Brazil. PLoS Neglected Tropical Diseases, 2014, 8, e3374.	1.3	50
271	Diagnosis of leishmaniasis. Journal of Infection in Developing Countries, 2014, 8, 961-972.	0.5	138

#	Article	IF	Citations
272	LmaPA2G4, a Homolog of Human Ebp1, Is an Essential Gene and Inhibits Cell Proliferation in L. major. PLoS Neglected Tropical Diseases, 2014, 8, e2646.	1.3	12
273	Immune Regulation during Chronic Visceral Leishmaniasis. PLoS Neglected Tropical Diseases, 2014, 8, e2914.	1.3	112
274	Visceral Leishmaniasis and HIV Coinfection: Time for Concerted Action. PLoS Neglected Tropical Diseases, 2014, 8, e3023.	1.3	23
275	Visceral Leishmaniasis and HIV Co-infection in Bihar, India: Long-term Effectiveness and Treatment Outcomes with Liposomal Amphotericin B (AmBisome). PLoS Neglected Tropical Diseases, 2014, 8, e3053.	1.3	51
276	Multiple Cutaneous Nodules in an HIV-Infected Patient. PLoS Neglected Tropical Diseases, 2014, 8, e3291.	1.3	13
277	Mucocutaneous Leishmaniasis/HIV Coinfection Presented as a Diffuse Desquamative Rash. Case Reports in Infectious Diseases, 2014, 2014, 1-5.	0.2	4
278	A Screen-and-Treat Strategy Targeting Visceral Leishmaniasis in HIV-Infected Individuals in Endemic East African Countries: The Way Forward?. PLoS Neglected Tropical Diseases, 2014, 8, e3011.	1.3	21
279	PKDL and Other Dermal Lesions in HIV Co-infected Patients with Leishmaniasis: Review of Clinical Presentation in Relation to Immune Responses. PLoS Neglected Tropical Diseases, 2014, 8, e3258.	1.3	63
280	Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease. Frontiers in Immunology, 2014, 5, 272.	2.2	73
281	The lost hope of elimination of Kala-azar (visceral leishmaniasis) by 2010 and cyclic occurrence of its outbreak in India, blame falls on vector control practices or co-infection with human immunodeficiency virus or therapeutic modalities?. Tropical Parasitology, 2014, 4, 10.	0.2	39
282	Atypical Presentation of PKDL due toLeishmania infantumin an HIV-Infected Patient with Relapsing Visceral Leishmaniasis. Case Reports in Infectious Diseases, 2014, 2014, 1-3.	0.2	17
283	Visceral Leishmaniasis as an AIDS Defining Condition: Towards Consistency across WHO Guidelines. PLoS Neglected Tropical Diseases, 2014, 8, e2916.	1.3	14
284	Strategies to Overcome Antileishmanial Drugs Unresponsiveness. Journal of Tropical Medicine, 2014, 2014, 1-7.	0.6	41
285	First case of pulmonary tuberculosis and visceral leishmaniasis coinfection successfully treated with antituberculosis drug and liposomal amphotericin B. Clinical Case Reports (discontinued), 2014, 2, 331-332.	0.2	7
286	Changing trends in the epidemiology, clinical presentation, and diagnosis of Leishmaniaâ€“HIV co-infection in India. International Journal of Infectious Diseases, 2014, 29, 103-112.	1.5	52
287	Leishmania amastigotes in the ascites of a HIVâ€positive patient. Diagnostic Cytopathology, 2014, 42, 428-430.	0.5	2
288	A 32-Year-Old Man From El Salvador With Fever, Weight Loss, and Splenomegaly. Clinical Infectious Diseases, 2014, 58, 746-747.	2.9	0
289	Concomitant Infection withLeishmania donovaniandL. majorin Single Ulcers of Cutaneous Leishmaniasis Patients from Sudan. Journal of Tropical Medicine, 2014, 2014, 1-8.	0.6	26

#	Article	IF	Citations
290	Parasitic Pneumonia and Lung Involvement. BioMed Research International, 2014, 2014, 1-18.	0.9	49
291	Characteristics of bacterial sepsis among patients with visceral leishmaniasis. Asian Pacific Journal of Tropical Biomedicine, 2014, 4, 871-875.	0.5	2
292	Leishmaniasis acquired by travellers to endemic regions in Europe: A EuroTravNet multi-centre study. Travel Medicine and Infectious Disease, 2014, 12, 167-172.	1.5	40
293	Moving from unsequenced to sequenced genome: Reanalysis of the proteome of Leishmania donovani. Journal of Proteomics, 2014, 97, 48-61.	1.2	40
294	1,3,4-Thiadiazole: Synthesis, Reactions, and Applications in Medicinal, Agricultural, and Materials Chemistry. Chemical Reviews, 2014, 114, 5572-5610.	23.0	430
295	Identification of Virulence Factors in Leishmania infantum Strains by a Proteomic Approach. Journal of Proteome Research, 2014, 13, 1860-1872.	1.8	39
296	CD4⁺T Cells: Guardians of the Phagosome. Clinical Microbiology Reviews, 2014, 27, 200-213.	5.7	78
297	Specific Noninvasive Detection of Leishmania donovani in Desquamated Buccal Cell Swab Samples from Human Visceral Leishmaniasis-HIV Coinfected Patients. Journal of Clinical Microbiology, 2014, 52, 1238-1241.	1.8	9
298	In Vitro Screening Test Using Leishmania Promastigotes Stably Expressing mCherry Protein. Antimicrobial Agents and Chemotherapy, 2014, 58, 1825-1828.	1.4	17
299	Discovery of novel anti-leishmanial agents targeting LdLip3 lipase. Journal of Molecular Graphics and Modelling, 2014, 49, 68-79.	1.3	8
300	Triazino indoleâ€“quinoline hybrid: A novel approach to antileishmanial agents. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 298-301.	1.0	40
301	Antileishmanial activity of 12-methoxycarnosic acid from Salvia repens Burch. ex Benth. (Lamiaceae). South African Journal of Botany, 2014, 90, 93-95.	1.2	21
302	Combination Therapy with Tamoxifen and Amphotericin B in Experimental Cutaneous Leishmaniasis. Antimicrobial Agents and Chemotherapy, 2014, 58, 2608-2613.	1.4	55
303	Characterization of the Proliferating Cell Nuclear Antigen of Leishmania donovani Clinical Isolates and Its Association with Antimony Resistance. Antimicrobial Agents and Chemotherapy, 2014, 58, 2997-3007.	1.4	16
304	Emergence of co-infection of visceral leishmaniasis in HIV-positive patients in northeast Iran: A preliminary study. Travel Medicine and Infectious Disease, 2014, 12, 173-178.	1.5	36
305	Leishmania panamensis infection and antimonial drugs modulate expression of macrophage drug transporters and metabolizing enzymes: impact on intracellular parasite survival. Journal of Antimicrobial Chemotherapy, 2014, 69, 139-149.	1.3	26
306	Leishmaniasis in travelers: A literature review. Travel Medicine and Infectious Disease, 2014, 12, 563-581.	1.5	103
307	Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis. Chemical Reviews, 2014, 114, 11305-11347.	23.0	274

#	Article	IF	Citations
308	LeishMan Recommendations for Treatment of Cutaneous and Mucosal Leishmaniasis in Travelers, 2014. Journal of Travel Medicine, 2014, 21, 116-129.	1.4	110
309	Leishmaniasis in immunosuppressed individuals. Clinical Microbiology and Infection, 2014, 20, 286-299.	2.8	266
310	Diverse modes of binding in structures ofLeishmania majorN-myristoyltransferase with selective inhibitors. IUCrJ, 2014, 1, 250-260.	1.0	38
311	The Impact of Human Immunodeficiency Virus (HIV) Co-Infection on the Economic Burden of Cutaneous Leishmaniasis (CL) in Brazil and Potential Value of New CL Drug Treatments. American Journal of Tropical Medicine and Hygiene, 2014, 91, 520-527.	0.6	3
312	Development of targeted 1,2-diacyl-sn-glycero-3-phospho-<scp>l</scp>-serine-coated gelatin nanoparticles loaded with amphotericin B for improvedin vitroandin vivoeffect in leishmaniasis. Expert Opinion on Drug Delivery, 2014, 11, 633-646.	2.4	47
313	Leishmaniasis and autoimmune diseases in pediatric age. Cellular Immunology, 2014, 292, 9-13.	1.4	14
314	New drugs with antiprotozoal activity from marine algae: a review. Revista Brasileira De Farmacognosia, 2014, 24, 265-276.	0.6	78
315	Assessment of the infectivity potential of Leishmania infantum, using flow cytometry. Experimental Parasitology, 2014, 145, 29-33.	0.5	1
316	Leishmanicidal Activities of Novel Synthetic Furoxan and Benzofuroxan Derivatives. Antimicrobial Agents and Chemotherapy, 2014, 58, 4837-4847.	1.4	36
317	A case of panuveitis with hypopyon due to presumed ocular leishmaniasis in a HIV patient. Journal of Ophthalmic Inflammation and Infection, 2014, 4, 21.	1.2	6
318	Role of wildlife in the epidemiology of Leishmania infantum infection in Europe. Parasitology Research, 2014, 113, 2005-2014.	0.6	112
319	Visceral leishmaniasis is associated with marked changes in serum lipid profile. European Journal of Clinical Investigation, 2014, 44, 719-727.	1.7	18
320	Multiple relapses of visceral leishmaniasis in a patient with HIV in India: A treatment challenge. International Journal of Infectious Diseases, 2014, 25, 204-206.	1.5	10
321	Catalytic activity of a novel serine/threonine protein phosphatase PP5 fromLeishmania major. Parasite, 2014, 21, 25.	0.8	7
322	Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease. The Cochrane Library, 2014, , CD009135.	1.5	93
323	Immunological consequences of stress-related proteins â€“ cytosolic tryparedoxin peroxidase and chaperonin TCP20 â€“ identified in splenic amastigotes ofLeishmania donovanias Th1 stimulatory, in experimental visceral leishmaniasis. Parasitology, 2015, 142, 728-744.	0.7	6
324	Impaired Tâ€cellâ€dependent protection against <scp>L</scp>eishmania major infection in <scp>HIV</scp>â€positive patients is associated with worsened disease outcome. Experimental Dermatology, 2015, 24, 302-304.	1.4	4
325	Multilocus microsatellite typing ofLeishmaniaand clinical applications: a review. Parasite, 2015, 22, 16.	0.8	9

#	Article	IF	Citations
326	Multilocus microsatellite typing of Leishmania infantum isolates in monitored Leishmania/HIV coinfected patients. Parasites and Vectors, 2015, 8, 386.	1.0	1
327	Neurological disease in human and canine leishmaniasis â€“ clinical features and immunopathogenesis. Parasite Immunology, 2015, 37, 385-393.	0.7	20
329	Human Vector-Borne Transmissible Parasitic Diseases in Montenegro. , 0, , .		1
330	Leptomonas seymouri: Adaptations to the Dixenous Life Cycle Analyzed by Genome Sequencing, Transcriptome Profiling and Co-infection with Leishmania donovani. PLoS Pathogens, 2015, 11, e1005127.	2.1	96
331	New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment. Revista Da Sociedade Brasileira De Medicina Tropical, 2015, 48, 235-242.	0.4	71
332	Leishmania Species. , 2015, , 3091-3107.e4.		15
333	Epidemiological Changes in Leishmaniasis in Spain According to Hospitalization-Based Records, 1997â€“2011: Raising Awareness towards Leishmaniasis in Non-HIV Patients. PLoS Neglected Tropical Diseases, 2015, 9, e0003594.	1.3	56
335	Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India. Clinical Infectious Diseases, 2015, 61, 1255-1262.	2.9	53
336	A Potential Role for Mononuclear Phagocytes in Cutaneous Ulcer Development in Human Immunodeficiency Virusâ€“Leishmania braziliensis Coinfection. American Journal of Tropical Medicine and Hygiene, 2015, 93, 1219-1223.	0.6	2
337	Anti-HIV drugs, lopinavir/ritonavir and atazanavir, modulate innate immune response triggered by Leishmania in macrophages: The role of NF-ÎºB and PPAR-Î³. International Immunopharmacology, 2015, 24, 314-324.	1.7	9
338	Visceral leishmaniasis as an independent cause of high immune activation, <scp>T</scp>â€cell senescence, and lack of immune recovery in virologically suppressed <scp>HIV</scp>â€1â€coinfected patients. HIV Medicine, 2015, 16, 240-248.	1.0	34
339	Leishmaniosis of companion animals in Europe: An update. Veterinary Parasitology, 2015, 208, 35-47.	0.7	80
340	High levels of CD4+ CTLA-4+ Treg cells and CCR5 density in HIV-1-infected patients with visceral leishmaniasis. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 267-275.	1.3	9
341	Mise au point et actualitÃ©s sur la leishmaniose viscÃ©rale mÃ©diterranÃ©enne. Journal Des Anti-infectieux, 2015, 17, 25-28.	0.1	1
342	Visceral leishmaniasis mimicking systemic lupus erythematosus: Case series and a systematic literature review. Seminars in Arthritis and Rheumatism, 2015, 44, 658-665.	1.6	28
343	Synthesis of carboxyimidamide-substituted benzo[c][1,2,5]oxadiazoles and their analogs, and evaluation of biological activity against Leishmania donovani. MedChemComm, 2015, 6, 1673-1678.	3.5	8
344	New World and Old World Leishmania Infections. Dermatologic Clinics, 2015, 33, 579-593.	1.0	230
345	Leishmaniasis revisited: Current aspects on epidemiology, diagnosis and treatment. Journal of Translational Internal Medicine, 2015, 3, 43-50.	1.0	128

#	Article	IF	Citations
346	Spatial distribution of human asymptomatic Leishmania infantum infection in southeast Spain: A study of environmental, demographic and social risk factors. Acta Tropica, 2015, 146, 127-134.	0.9	35
347	In vitro and in vivo evaluation of anti-leishmanial and immunomodulatory activity of Neem leaf extract in Leishmania donovani infection. Experimental Parasitology, 2015, 153, 45-54.	0.5	33
348	HIV and parasite co-infection epidemiology. Reviews in Medical Microbiology, 2015, 26, 20-25.	0.4	2
349	Visceral Leishmaniasis/HIV co-infection in northeast Brazil: evaluation of outcome. Brazilian Journal of Infectious Diseases, 2015, 19, 651-656.	0.3	29
350	Rapid Tests and the Diagnosis of Visceral Leishmaniasis and Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Coinfection. American Journal of Tropical Medicine and Hygiene, 2015, 93, 967-969.	0.6	25
351	Leishmaniasis: diagnostic issues in Europe. Expert Review of Anti-Infective Therapy, 2015, 13, 1123-1138.	2.0	14
352	Clinical aspects of paediatric visceral leishmaniasis in <scp>N</scp>orthâ€west <scp>E</scp>thiopia. Tropical Medicine and International Health, 2015, 20, 8-16.	1.0	30
353	Visceral leishmaniasis in a patient with systemic lupus erythematosus. IDCases, 2015, 2, 102-105.	0.4	4
354	Immunological comparison of DNA vaccination using two delivery systems against canine leishmaniasis. Veterinary Parasitology, 2015, 212, 130-139.	0.7	28
355	Investigational drugs for visceral leishmaniasis. Expert Opinion on Investigational Drugs, 2015, 24, 43-59.	1.9	44
356	Atypical manifestations of visceral leishmaniasis in patients with HIV in north Ethiopia: a gap in guidelines for the management of opportunistic infections in resource poor settings. Lancet Infectious Diseases, The, 2015, 15, 122-129.	4.6	31
357	Preliminary survey of domestic animal visceral leishmaniasis and risk factors in northâ€west Ethiopia. Tropical Medicine and International Health, 2015, 20, 205-210.	1.0	26
358	First Case of Visceral Leishmaniasis Caused by Leishmania martiniquensis. American Journal of Tropical Medicine and Hygiene, 2015, 92, 317-319.	0.6	32
359	An update on pharmacotherapy for leishmaniasis. Expert Opinion on Pharmacotherapy, 2015, 16, 237-252.	0.9	213
360	Specific antibody responses as indicators of treatment efficacy for visceral leishmaniasis. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 679-686.	1.3	16
361	Epidemiology of human immunodeficiency virus-visceral leishmaniasis-co-infection. Journal of Microbiology, Immunology and Infection, 2016, 49, 295-299.	1.5	5
362	Nutritional supplements for patients being treated for active visceral leishmaniasis. The Cochrane Library, 2016, , .	1.5	3
363	Predicting death from kala-azar: construction, development, and validation of a score set and accompanying software. Revista Da Sociedade Brasileira De Medicina Tropical, 2016, 49, 728-740.	0.4	29

#	Article	IF	Citations
364	Pro- and Anti-inflammatory Cytokines in Visceral Leishmaniasis. Journal of Cell Science & Therapy, 2016, 06, .	0.3	6
365	Leishmaniose visceral infantil: relato de caso. , 2016, 95, 133.	0.0	0
366	Sandfly and Leishmaniasis: A Review. Journal of Ecosystem & Ecography, 2016, 6, .	0.2	8
367	Leishmania infantumGenetic Diversity andLutzomyia longipalpisMitochondrial Haplotypes in Brazil. BioMed Research International, 2016, 2016, 1-11.	0.9	8
368	Leishmaniasis–HIV coinfection: current challenges. HIV/AIDS - Research and Palliative Care, 2016, Volume 8, 147-156.	0.4	70
369	Seroepidemiology and molecular diversity of Leishmania donovani complex in Georgia. Parasites and Vectors, 2016, 9, 279.	1.0	6
370	Exploring the unbinding ofLeishmania(L.)amazonensisCPB derived-epitopes from H2 MHC class I proteins. Proteins: Structure, Function and Bioinformatics, 2016, 84, 473-487.	1.5	14
371	Answer to July 2016 Photo Quiz. Journal of Clinical Microbiology, 2016, 54, 1935-1936.	1.8	0
372	<scp>CC</scp> chemokine receptor 5 Î”32 polymorphism: association analysis and allele distribution among cutaneous leishmaniasis patients from Pakistan. Journal of Cutaneous Pathology, 2016, 43, 564-570.	0.7	6
373	Decentralized control of human visceral leishmaniasis in endemic urban areas of Brazil: a literature review. Tropical Medicine and Health, 2016, 44, 9.	1.0	14
374	The immunology of post-kala-azar dermal leishmaniasis (PKDL). Parasites and Vectors, 2016, 9, 464.	1.0	93
375	Antileishmanial activity and mechanism of action from a purified fraction of Zingiber officinalis Roscoe against Leishmania amazonensis. Experimental Parasitology, 2016, 166, 21-28.	0.5	31
376	Severe Cutaneous Leishmaniasis in a Human Immunodeficiency Virus Patient Coinfected with Leishmania braziliensis and Its Endosymbiotic Virus. American Journal of Tropical Medicine and Hygiene, 2016, 94, 840-843.	0.6	27
377	Expeditious synthesis of the tetrasaccharide cap domain of the Leishmania donovani lipophosphoglycan using one-pot glycosylation reactions. RSC Advances, 2016, 6, 45112-45119.	1.7	7
378	Risk Profiles for Leishmania infantum Infection in Brazil. American Journal of Tropical Medicine and Hygiene, 2016, 94, 1276-1281.	0.6	5
379	A review of visceral leishmaniasis during the conflict in South Sudan and the consequences for East African countries. Parasites and Vectors, 2016, 9, 460.	1.0	80
380	Elimination of visceral leishmaniasis on the Indian subcontinent. Lancet Infectious Diseases, The, 2016, 16, e304-e309.	4.6	98
381	Worldwide risk factors in leishmaniasis. Asian Pacific Journal of Tropical Medicine, 2016, 9, 925-932.	0.4	180

#	Article	IF	Citations
382	Evaluation of urine for Leishmania infantum DNA detection by real-time quantitative PCR. Journal of Microbiological Methods, 2016, 131, 34-41.	0.7	20
383	Biocompatible silver nanoparticles reduced from Anethum graveolens leaf extract augments the antileishmanial efficacy of miltefosine. Experimental Parasitology, 2016, 170, 184-192.	0.5	56
384	Immunoprotective effect of lentinan in combination with miltefosine on Leishmaniaâ€‹infected Jâ€‹774A.1 macrophages. Parasite Immunology, 2016, 38, 618-627.	0.7	22
385	Lymphoproliferative response after stimulation with soluble leishmania antigen (SLA) as a predictor of visceral leishmaniasis (VL) relapse in HIV+ patients. Acta Tropica, 2016, 164, 345-351.	0.9	12
386	Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clinical Infectious Diseases, 2016, 63, e202-e264.	2.9	235
387	Acetyl shikonin induces IL-12, nitric oxide and ROS to kill intracellular parasite Leishmania donovani in infected hosts. RSC Advances, 2016, 6, 61777-61783.	1.7	11
389	Recent developments and future prospects in the treatment of visceral leishmaniasis. Therapeutic Advances in Infectious Disease, 2016, 3, 98-109.	1.1	99
390	The unwelcome trio: HIV plus cutaneous and visceral leishmaniasis. Dermatologic Therapy, 2016, 29, 88-91.	0.8	14
392	Mathematical analysis of a model for AVLâ€“HIV co-endemicity. Mathematical Biosciences, 2016, 271, 80-95.	0.9	19
393	Evaluation of two recombinant Leishmania proteins identified by an immunoproteomic approach as tools for the serodiagnosis of canine visceral and human tegumentary leishmaniasis. Veterinary Parasitology, 2016, 215, 63-71.	0.7	25
394	Visceral leishmaniasis: a forgotten epidemic. Archives of Disease in Childhood, 2016, 101, 561-567.	1.0	22
396	Development of visceral leishmaniasis in an HIV+ patient upon immune reconstitution following the initiation of antiretroviral therapy. Infection, 2016, 44, 115-119.	2.3	3
397	Anti-leishmanial activity of Brazilian green, brown, and red algae. Journal of Applied Phycology, 2016, 28, 591-598.	1.5	14
398	Conjunctival leishmaniasis in a case of disseminated cutaneous leishmaniasis. Tropical Doctor, 2017, 47, 53-55.	0.2	6
399	Prevalence of Human Immunodeficiency Virus and associated factors among Visceral Leishmaniasis infected patients in Northwest Ethiopia: a facility based cross-sectional study. BMC Infectious Diseases, 2017, 17, 152.	1.3	15
400	Intraspecific genetic variability in a population of Moroccan Leishmania infantum revealed by PCR-RFLP of kDNA minicircles. Acta Tropica, 2017, 169, 142-149.	0.9	12
401	Managing two decades of visceral leishmaniasis and HIV co-infection: a case report that illustrates the urgent research needs in the field. Sexual Health, 2017, 14, 286.	0.4	1
402	Coinfection of Leishmania guyanensis and Human Immunodeficiency Virusâ€“Acquired Immune Deficiency Syndrome: Report of a Case of Disseminated Cutaneous Leishmaniasis in Ecuador. American Journal of Tropical Medicine and Hygiene, 2017, 96, 16-0431.	0.6	8

#	Article	IF	Citations
403	Drug Resistance in Leishmania. , 2017, , 313-341.		7
404	Visceral leishmaniosis in immunocompromised host: an update and literature review. Journal of Chemotherapy, 2017, 29, 261-266.	0.7	31
405	Application of nanotechnology in treatment of leishmaniasis: A Review. Acta Tropica, 2017, 172, 86-90.	0.9	106
406	What pre-Columbian mummies could teach us about South American leishmaniases?. Pathogens and Disease, 2017, 75, .	0.8	4
407	Atypical presentations of cutaneous leishmaniasis: A systematic review. Acta Tropica, 2017, 172, 240-254.	0.9	83
408	An in silico functional annotation and screening of potential drug targets derived from Leishmania spp. hypothetical proteins identified by immunoproteomics. Experimental Parasitology, 2017, 176, 66-74.	0.5	15
409	Causes and consequences of higher Leishmania infantum burden in patients with kalaâ€azar: a study of 625 patients. Tropical Medicine and International Health, 2017, 22, 679-687.	1.0	33
410	Leishmania donovani resistant to Ambisome or Miltefosine exacerbates CD58 expression on NK cells and promotes trans-membrane migration in association with CD2. Cytokine, 2017, 96, 54-58.	1.4	5
411	Perceived quality of life among Visceral Leishmaniasis and HIV coinfected migrant male-workers in Northwest Ethiopia: a qualitative study. BMC Public Health, 2017, 17, 204.	1.2	5
412	Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). American Journal of Tropical Medicine and Hygiene, 2017, 96, 24-45.	0.6	191
414	MAPK1 of Leishmania donovani interacts and phosphorylates HSP70 and HSP90 subunits of foldosome complex. Scientific Reports, 2017, 7, 10202.	1.6	28
415	Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies. Journal of Clinical Immunology, 2017, 37, 650-692.	2.0	6
418	Tropical Parasitic Infections in Individuals Infected With HIV. Current Tropical Medicine Reports, 2017, 4, 268-280.	1.6	3
419	Cutaneous and visceral leishmaniasis during anti-TNFÎ± therapy. Wiener Medizinische Wochenschrift, 2017, 167, 78-82.	0.5	12
420	Antileishmanial activity of selected South African plant species. South African Journal of Botany, 2017, 108, 342-345.	1.2	15
421	Protective Efficacy of Secondary Prophylaxis Against Visceral Leishmaniasis in Human Immunodeficiency Virus Coinfected Patients Over the Past 10 Years in Eastern India. American Journal of Tropical Medicine and Hygiene, 2017, 96, 285-291.	0.6	9
422	Changing epidemiology of visceral leishmaniasis in northeastern Brazil: a 25-year follow-up of an urban outbreak. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2017, 111, 440-447.	0.7	31
423	Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis. Mini-Reviews in Medicinal Chemistry, 2017, 18, 26-41.	1.1	69

#	Article	IF	Citations
424	Standardization and evaluation of a duplex real-time quantitative PCR for the detection of Leishmania infantum DNA: a sample quality control approach. Revista Da Sociedade Brasileira De Medicina Tropical, 2017, 50, 350-357.	0.4	5
425	Alternative to Chemotherapyâ€"The Unmet Demand against Leishmaniasis. Frontiers in Immunology, 2017, 8, 1779.	2.2	34
426	Changes in the epidemiology of visceral leishmaniasis in Brazil from 2001 to 2014. Revista Da Sociedade Brasileira De Medicina Tropical, 2017, 50, 638-645.	0.4	49
427	Characterization of Leishmania (L.) infantum chagasi in visceral leishmaniasis associated with hiv co-infection in Northeastern Brazil. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2017, 59, e48.	0.5	6
428	Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS Neglected Tropical Diseases, 2017, 11, e0006052.	1.3	571
429	Clinical and parasitological factors in parasite persistence after treatment and clinical cure of cutaneous leishmaniasis. PLoS Neglected Tropical Diseases, 2017, 11, e0005713.	1.3	39
430	Does timing of antiretroviral treatment influence treatment outcomes of visceral leishmaniasis in Northwest Ethiopia?. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2017, 111, 107-116.	0.7	5
431	Profile of Patientsâ€™ Visceral Leishmaniasis-HIV co-infection in Kabylia. Journal of AIDS & Clinical Research, 2017, 08, .	0.5	0
432	The Risk and Predictors of Visceral Leishmaniasis Relapse in Human Immunodeficiency Virus-Coinfected Patients in Ethiopia: A Retrospective Cohort Study. Clinical Infectious Diseases, 2017, 65, 1703-1710.	2.9	34
433	Epidemiological profile of patients co-infected with visceral leishmaniasis and HIV/AIDS in Northeast, Brazil. Revista Da Sociedade Brasileira De Medicina Tropical, 2017, 50, 613-620.	0.4	9
434	Human visceral leishmaniasis: factors associated with deaths in Belo Horizonte, Minas Gerais state, Brazil from 2006 to 2013. Epidemiology and Infection, 2018, 146, 565-570.	1.0	15
435	Is Visceral Leishmaniasis the same in HIV-coinfected adults?. Brazilian Journal of Infectious Diseases, 2018, 22, 92-98.	0.3	21
436	Leishmania Species (Leishmaniasis). , 2018, , 1323-1334.e3.		1
438	Treatment of Visceral Leishmaniasis. , 2018, , 169-190.		1
439	Treatment of Tegumentary Forms of Leishmaniasis. , 2018, , 191-225.		1
440	Performance of two immunochromatographic tests for diagnosis of visceral leishmaniasis in patients coinfected with HIV. Parasitology Research, 2018, 117, 419-427.	0.6	17
441	The Leishmaniases: Old Neglected Tropical Diseases. , 2018, , .		35
442	Nutritional supplements for patients being treated for active visceral leishmaniasis. The Cochrane Library, 2018, 3, CD012261.	1.5	7

#	Article	IF	Citations
443	Association between canine leishmaniosis and Ehrlichia canis co-infection: a prospective case-control study. Parasites and Vectors, 2018, 11, 184.	1.0	34
444	Using proteomics as a powerful tool to develop a vaccine against Mediterranean visceral leishmaniasis. Journal of Parasitic Diseases, 2018, 42, 162-170.	0.4	10
445	Chemotherapy of leishmaniasis: present challenges. Parasitology, 2018, 145, 464-480.	0.7	153
446	Long-term Clinical Outcomes in Visceral Leishmaniasis/Human Immunodeficiency Virusâ€“Coinfected Patients During and After Pentamidine Secondary Prophylaxis in Ethiopia: A Single-Arm Clinical Trial. Clinical Infectious Diseases, 2018, 66, 444-451.	2.9	26
447	Chemotherapeutics of visceral leishmaniasis: present and future developments. Parasitology, 2018, 145, 481-489.	0.7	90
448	Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs. Clinical Pharmacokinetics, 2018, 57, 151-176.	1.6	55
449	Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art. Parasitology, 2018, 145, 219-236.	0.7	81
450	Double Infection With Leishmania tropica and L. major in an HIV Patient Controlled With High Doses of Amphotericin B. Open Forum Infectious Diseases, 2018, 5, ofy323.	0.4	7
451	The Polyamine Pathway as a Potential Target for Leishmaniases Chemotherapy. , 0, , .		2
452	Barriers to access to visceral leishmaniasis diagnosis and care among seasonal mobile workers in Western Tigray, Northern Ethiopia: A qualitative study. PLoS Neglected Tropical Diseases, 2018, 12, e0006778.	1.3	10
453	Development of a sandwich ELISA to detect Leishmania 40S ribosomal protein S12 antigen from blood samples of visceral leishmaniasis patients. BMC Infectious Diseases, 2018, 18, 500.	1.3	16
454	Monocyte subpopulations as important biomarkers of resistence and susceptibility during experimental infection with Leishmania (Leishmania) major. Biomedicine and Pharmacotherapy, 2018, 107, 1530-1539.	2.5	0
455	Co-infection with HIV. , 2018, , 145-158.		0
456	Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives. Clinical Microbiology Reviews, 2018, 31, .	5.7	145
457	Epidemiological, clinical and laboratory aspects of human visceral leishmaniasis (HVL) associated with human immunodeficiency virus (HIV) coinfection: a systematic review. Parasitology, 2018, 145, 1801-1818.	0.7	15
458	Lopinavir, an HIV-1 peptidase inhibitor, induces alteration on the lipid metabolism ofLeishmania amazonensispromastigotes. Parasitology, 2018, 145, 1304-1310.	0.7	13
459	Phytodrugs and Immunomodulators for the Therapy of Leishmaniasis. , 2018, , 213-275.		5
460	New insights into leishmaniasis in the immunosuppressed. PLoS Neglected Tropical Diseases, 2018, 12, e0006375.	1.3	75

#	Article	IF	Citations
461	Hematologic Aspects of Parasitic Diseases. , 2018, , 2278-2303.e6.		3
462	Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients. Frontiers in Immunology, 2017, 8, 1943.	2.2	32
463	Analysis of genetic polymorphisms and tropism in East African Leishmania donovani by Amplified Fragment Length Polymorphism and kDNA minicircle sequencing. Infection, Genetics and Evolution, 2018, 65, 80-90.	1.0	10
464	HIV aspartyl protease inhibitors modify the percentage of activated leukocytes, as well as serum levels of IL-17A and NO during experimental leishmaniasis. International Immunopharmacology, 2018, 60, 179-188.	1.7	2
465	Drug Resistance in Leishmania Parasites. , 2018, , .		3
466	Leishmaniasis: The Biology of a Parasite. , 2018, , 1-16.		2
467	Visceral Leishmaniasis. , 2018, , 159-176.		3
468	The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study. PLoS Neglected Tropical Diseases, 2018, 12, e0006527.	1.3	19
469	Leishmaniasis in Ethiopia: A systematic review and meta-analysis of prevalence in animals and humans. Heliyon, 2018, 4, e00723.	1.4	31
470	Cyclic Nucleotide-Specific Phosphodiesterases as Potential Drug Targets for Anti-Leishmania Therapy. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	17
471	Leishmaniasis. Lancet, The, 2018, 392, 951-970.	6.3	1,264
472	The criminal association of Leishmania parasites and viruses. Current Opinion in Microbiology, 2018, 46, 65-72.	2.3	8
473	Visceral leishmaniasis in hematopoietic cell transplantation: Case report and review of the literature. Journal of Infection and Chemotherapy, 2018, 24, 990-994.	0.8	14
474	High frequency of subclinical Leishmania infection among HIV-infected patients living in the endemic areas of visceral leishmaniasis in Fars province, southern Iran. Parasitology Research, 2018, 117, 2591-2595.	0.6	13
475	Detection of Leishmania DNA in saliva among patients with HIV/AIDS in Trang Province, southern Thailand. Acta Tropica, 2018, 185, 294-300.	0.9	11
476	Application of Dithiocarbamates as Potential New Antitrypanosomatids-Drugs: Approach Chemistry, Functional and Biological. Molecules, 2019, 24, 2806.	1.7	43
477	Clinical aspects of visceral leishmaniasis caused by L. infantum in adults. Ten years of experience of the largest outbreak in Europe: what have we learned?. Parasites and Vectors, 2019, 12, 359.	1.0	30
478	Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases. Expert Opinion on Drug Delivery, 2019, 16, 1063-1079.	2.4	43

#	Article	IF	Citations
479	Recent autochthonous cases of leishmaniasis in residents of the Republic of Dagestan, Russian Federation. International Journal of Infectious Diseases, 2019, 86, 171-174.	1.5	4
480	A nationwide survey of Leishmania infantum infection in cats and associated risk factors in Italy. PLoS Neglected Tropical Diseases, 2019, 13, e0007594.	1.3	45
481	Miltefosine-Lopinavir Combination Therapy Against Leishmania infantum Infection: In vitro and in vivo Approaches. Frontiers in Cellular and Infection Microbiology, 2019, 9, 229.	1.8	19
482	Leishmania speciesâ€dependent functional duality of tollâ€like receptor 2. IUBMB Life, 2019, 71, 1685-1700.	1.5	22
483	Longitudinal evaluation of asymptomatic Leishmania infection in HIV-infected individuals in North-West Ethiopia: A pilot study. PLoS Neglected Tropical Diseases, 2019, 13, e0007765.	1.3	19
484	An Unusual Case of Feline Leishmaniosis With Involvement of the Mammary Glands. Topics in Companion Animal Medicine, 2019, 37, 100356.	0.4	12
485	Biochemical characterization and chemical validation of Leishmania MAP Kinase-3 as a potential drug target. Scientific Reports, 2019, 9, 16209.	1.6	17
486	Risk mapping of human HIV-Leishmaniasis co-infection in Morocco. Heliyon, 2019, 5, e02419.	1.4	3
487	Anti-leishmanial and Anti-inflammatory Agents from Endophytes: A Review. Natural Products and Bioprospecting, 2019, 9, 311-328.	2.0	23
488	Leishmaniasis in Northern Morocco: Predominance of Leishmania infantum Compared to Leishmania tropica. BioMed Research International, 2019, 2019, 1-14.	0.9	13
489	A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia. PLoS Neglected Tropical Diseases, 2019, 13, e0006988.	1.3	47
490	How cutaneous leishmaniasis and treatment impacts in the patientsâ€™ lives: A cross-sectional study. PLoS ONE, 2019, 14, e0211374.	1.1	12
491	Visceral Leishmaniasis. Infectious Disease Clinics of North America, 2019, 33, 79-99.	1.9	99
492	Asymptomatic immune responders to Leishmania among HIV positive patients. PLoS Neglected Tropical Diseases, 2019, 13, e0007461.	1.3	22
493	Epidemiology of visceral leishmaniasis in Shebelle Zone of Somali Region, eastern Ethiopia. Parasites and Vectors, 2019, 12, 209.	1.0	13
494	Current and emerging medications for the treatment of leishmaniasis. Expert Opinion on Pharmacotherapy, 2019, 20, 1251-1265.	0.9	114
495	An immunoproteomic approach to identifying immunoreactive proteins inLeishmania infantumamastigotes using sera of dogs infected with canine visceral leishmaniasis. Pathogens and Global Health, 2019, 113, 124-132.	1.0	10
496	Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy. Frontiers in Immunology, 2019, 10, 670.	2.2	136

#	Article	IF	Citations
497	Therapeutic Leishmaniasis: Recent Advancement and Developments in Nanomedicines. , 2019, , 195-220.		6
498	Health Considerations for HIV-Infected International Travelers. Current Infectious Disease Reports, 2019, 21, 16.	1.3	4
500	Synthesis, Characterization, and Antileishmanial Activity of Certain Quinoline-4-carboxylic Acids. Journal of Chemistry, 2019, 2019, 1-9.	0.9	14
501	Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia. PLoS Neglected Tropical Diseases, 2019, 13, e0007132.	1.3	21
502	Visceral leishmaniasis in Northeast Brazil: What is the impact of HIV on this protozoan infection?. PLoS ONE, 2019, 14, e0225875.	1.1	9
503	Leishmanicidal therapy targeted to parasite proteases. Life Sciences, 2019, 219, 163-181.	2.0	24
504	Leishmaniasis: treatment, drug resistance and emerging therapies. Expert Opinion on Orphan Drugs, 2019, 7, 1-10.	0.5	38
505	Understanding the economic impact of leishmaniasis on households in endemic countries: a systematic review. Expert Review of Anti-Infective Therapy, 2019, 17, 57-69.	2.0	26
506	Congenital Leishmaniasis in a Newborn Infant Whose Mother was Coinfected With Leishmaniasis and HIV. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 277-280.	0.6	4
508	Cutaneous leishmaniasis: A great imitator. Clinics in Dermatology, 2020, 38, 140-151.	0.8	59
509	One Health Approach to Leishmaniases: Understanding the Disease Dynamics through Diagnostic Tools. Pathogens, 2020, 9, 809.	1.2	41
510	A rare case of lupoid leishmaniasis defying diagnosis for a decade. Journal of Cutaneous Pathology, 2020, 47, 1054-1057.	0.7	1
511	Recent advances and new strategies on leishmaniasis treatment. Applied Microbiology and Biotechnology, 2020, 104, 8965-8977.	1.7	107
512	Urine-Based Antigen (Protein) Detection Test for the Diagnosis of Visceral Leishmaniasis. Microorganisms, 2020, 8, 1676.	1.6	4
513	A spotlight on the diagnostic methods of a fatal disease Visceral Leishmaniasis. Parasite Immunology, 2020, 42, e12727.	0.7	33
514	Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV. EBioMedicine, 2020, 55, 102748.	2.7	16
515	Goldâ€“Silver Bimetallic Nanoparticles Reduced with Herbal Leaf Extracts Induce ROS-Mediated Death in Both Promastigote and Amastigote Stages of Leishmania donovani. ACS Omega, 2020, 5, 16238-16245.	1.6	35
516	Leishmania Encodes a Bacterium-like 2,4-Dienoyl-Coenzyme A Reductase That Is Required for Fatty Acid Î²-Oxidation and Intracellular Parasite Survival. MBio, 2020, 11, .	1.8	8

#	Article	IF	Citations
517	Leishmaniasis diagnosis: an update on the use of parasitological, immunological and molecular methods. Journal of Parasitic Diseases, 2020, 44, 253-272.	0.4	63
518	Microscopic and molecular evidence in support of rodent as a reservoir for dissemination of Leishmaniasis. Microscopy Research and Technique, 2020, 83, 729-735.	1.2	0
519	Evaluation of six commercial kits for the serological diagnosis of Mediterranean visceral leishmaniasis. PLoS Neglected Tropical Diseases, 2020, 14, e0008139.	1.3	12
520	Prevalence estimates of human immunodeficiency virus (HIV) infection among visceral leishmaniasis infected people in Northwest Ethiopia: a systematic review and meta-analysis. BMC Infectious Diseases, 2020, 20, 214.	1.3	11
521	Multiple Relapses of Visceral Leishmaniasis in HIV Co-Infected Patients: A Case Series from Ethiopia. Current Therapeutic Research, 2020, 92, 100583.	0.5	15
522	Cutaneous leishmaniasis in north-central Ethiopia: trend, clinical forms, geographic distribution, and determinants. Tropical Medicine and Health, 2020, 48, 39.	1.0	13
523	Quality of life perceptions amongst patients co-infected with Visceral Leishmaniasis and HIV: AÂqualitative study from Bihar, India. PLoS ONE, 2020, 15, e0227911.	1.1	7
524	Co-circulation of Toscana virus and Leishmania infantum in a focus of zoonotic visceral leishmaniasis from Central Tunisia. Acta Tropica, 2020, 204, 105342.	0.9	11
525	Antileishmanial activity of Urtica dioica extract against zoonotic cutaneous leishmaniasis. PLoS Neglected Tropical Diseases, 2020, 14, e0007843.	1.3	35
526	An immunoproteomics approach to identifyLeishmania infantumproteins to be applied for the diagnosis of visceral leishmaniasis and human immunodeficiency virus co-infection. Parasitology, 2020, 147, 932-939.	0.7	7
527	The advantages of nanomedicine in the treatment of visceral leishmaniasis: between sound arguments and wishful thinking. Expert Opinion on Drug Delivery, 2021, 18, 471-487.	2.4	2
528	Sonographic findings in visceral leishmaniasis â€“ A narrative review. Travel Medicine and Infectious Disease, 2021, 39, 101924.	1.5	8
529	Biomarkers of the early response to treatment of visceral leishmaniasis: A prospective cohort study. Parasite Immunology, 2021, 43, e12797.	0.7	6
530	Epidemiological profile and lethality of visceral leishmaniasis/human immunodeficiency virus co-infection in an endemic area in Northeast Brazil. Revista Da Sociedade Brasileira De Medicina Tropical, 2021, 54, e0795.	0.4	6
531	ENT Involvement in Leishmania Infections. Acta Otorrinolaringologica (English Edition), 2021, 72, 3-10.	0.1	0
532	Cutaneous leishmaniasis in Louisiana - one-year follow-up: A case report. World Journal of Clinical Infectious Diseases, 2021, 11, 19-26.	0.5	0
533	Asymptomatic Leishmania infection in HIV-positive outpatients on antiretroviral therapy in Pernambuco, Brazil. PLoS Neglected Tropical Diseases, 2021, 15, e0009067.	1.3	10
534	Improving the miltefosine efficacy against leishmaniasis by using different nanoassemblies made from surfactants or amphiphilic antimony (V) complex. , 2021, , 253-290.		1

#	Article	IF	Citations
536	Drug resistance and repurposing of existing drugs in Leishmaniasis. , 2021, , 103-124.		3
537	The Synergistic Relationship Between Climate Change and the HIV/AIDS Epidemic: A Conceptual Framework. AIDS and Behavior, 2021, 25, 2266-2277.	1.4	20
538	Modern Drug Discovery and Development in the Area of Leishmaniasis. , 2021, , 123-158.		3
539	Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study. Journal of Antimicrobial Chemotherapy, 2021, 76, 1258-1268.	1.3	8
540	A Molecular Modeling Approach to Identify Potential Antileishmanial Compounds Against the Cell Division Cycle (cdc)-2-Related Kinase 12 (CRK12) Receptor of Leishmania donovani. Biomolecules, 2021, 11, 458.	1.8	19
541	Development and Evaluation of Active Case Detection Methods to Support Visceral Leishmaniasis Elimination in India. Frontiers in Cellular and Infection Microbiology, 2021, 11, 648903.	1.8	7
542	Visceral Leishmaniasis-HIV Coinfection as a Predictor of Increased Leishmania Transmission at the Village Level in Bihar, India. Frontiers in Cellular and Infection Microbiology, 2021, 11, 604117.	1.8	15
543	Leishmaniasis in the United States: Emerging Issues in a Region of Low Endemicity. Microorganisms, 2021, 9, 578.	1.6	38
544	Case Report: Leishmania and HIV Co-Diagnosis: How to Understand Medical History?. Frontiers in Immunology, 2021, 12, 669723.	2.2	4
545	Anfotericina B liposomal en el tratamiento de la leishmaniasis visceral. Revista Iberoamericana De Micologia, 2021, 38, 101-104.	0.4	3
546	Leishmaniasis: where are we and where are we heading?. Parasitology Research, 2021, 120, 1541-1554.	0.6	56
547	Cutaneous and Mucocutaneous Leishmaniasis. Actas Dermo-sifiliogrÃ¡ficas, 2021, , .	0.2	13
548	In Vitro Susceptibility of Kinetoplastids to Celastroloids from Maytenus chiapensis. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	5
549	Domestic mammals as reservoirs for Leishmania donovani on the Indian subcontinent: Possibility and consequences on elimination. Transboundary and Emerging Diseases, 2022, 69, 268-277.	1.3	18
550	Garcinol from Garcinia indica inhibits HIVâ€1 reverse transcriptaseâ€associated ribonuclease H. Archiv Der Pharmazie, 2021, 354, e2100123.	2.1	6
551	Vulnerabilities to and the Socioeconomic and Psychosocial Impacts of the Leishmaniases: A Review. Research and Reports in Tropical Medicine, 2021, Volume 12, 135-151.	2.8	11
552	Effect of rK39 testing in guiding treatment initiation and outcome in patients with visceral leishmaniasis in Ethiopia: A prospective cohort study. PLoS ONE, 2021, 16, e0253303.	1.1	3
553	The HIVÂâ^Â1 protease inhibitor Amprenavir targets Leishmania donovani topoisomerase I and induces oxidative stress-mediated programmed cell death. Parasitology International, 2021, 82, 102287.	0.6	9

#	Article	IF	Citations
554	Case Report: Atypical Presentation of Visceral Leishmaniasis: Two Cases from Northwest Ethiopia. American Journal of Tropical Medicine and Hygiene, 2021, 104, 2082-2084.	0.6	1
555	The Leishmania antigen-specific pro-inflammatory response in cutaneous leishmaniasis is linked to disease progression but not to the therapeutic failure of pentavalent antimonials. Microbes and Infection, 2021, 23, 104866.	1.0	0
556	Leishmaniasis cutÃ¡nea y mucocutÃ¡nea. Actas Dermo-sifiliogrÃ¡ficas, 2021, 112, 601-618.	0.2	38
557	Utility of the Loop-Mediated Isothermal Amplification Assay for the Diagnosis of Visceral Leishmaniasis from Blood Samples in Ethiopia. American Journal of Tropical Medicine and Hygiene, 2021, 105, 1050-1055.	0.6	3
558	Diagnostic application of sensitive and specific phage-exposed epitopes for visceral leishmaniasis and human immunodeficiency virus coinfection. Parasitology, 2021, 148, 1706-1714.	0.7	3
559	Mitogen-Activated Protein Kinase and Aquaglyceroporin Gene Expression in Treatment Failure Leishmania major. Acta Parasitologica, 2021, , 1.	0.4	2
560	Knowledge, attitude and practices towards visceral leishmaniasis among HIV patients: A cross-sectional study from Bihar, India. PLoS ONE, 2021, 16, e0256239.	1.1	9
561	Novel azoles with potent antileishmanial activity. Future Microbiology, 2021, 16, 871-877.	1.0	1
562	Thermoresponsive Copolymer Nanovectors Improve the Bioavailability of Retrograde Inhibitors in the Treatment of Leishmania Infections. Frontiers in Cellular and Infection Microbiology, 2021, 11, 702676.	1.8	0
563	Organotin (IV) complexes with sulphonyl hydrazide moiety. Design, synthesis, characterization, docking studies, cytotoxic and anti-leishmanial activity. Journal of Biomolecular Structure and Dynamics, 2022, 40, 12336-12346.	2.0	2
565	Synthesis of limonene Î²-amino alcohol from (R)-(+)-Î±-methylbenzylamine and (+)-limonene 1,2-epoxide. Journal of Molecular Structure, 2021, 1241, 130691.	1.8	2
566	An overview of the fatty acid biosynthesis in the protozoan parasite Leishmania and its relevance as a drug target against leishmaniasis. Molecular and Biochemical Parasitology, 2021, 246, 111416.	0.5	7
567	ImplicaciÃ³n ORL en infecciones por Leishmania. Acta OtorrinolaringolÃ³gica EspaÃ±ola, 2021, 72, 3-10.	0.2	2
568	Leishmaniasis: An overview. , 2021, , 1-15.		0
570	Recent Developments in the Interactions Between Caveolin and Pathogens. Advances in Experimental Medicine and Biology, 2012, 729, 65-82.	0.8	23
571	Leishmaniasis: Challenges in the Control and Eradication. , 2013, , 247-264.		2
572	Leishmania Species. , 2010, , 3463-3480.		5
573	Bacterial, Parasitic, and Fungal Infections of the Liver, Including Liver Abscess. , 2010, , 1351-1369.e4.		2

#	Article	IF	Citations
574	Progress in the Mathematical Modelling of Visceral Leishmaniasis. Advances in Parasitology, 2016, 94, 49-131.	1.4	25
575	I. Appraisal of Leishmaniasis Chemotherapy, Current Status and Pipeline StrategiesChapter 1. Leishmaniasis, Impact and Therapeutic Needs. RSC Drug Discovery Series, 2017, , 1-23.	0.2	8
576	Molecular Basis of Drug Resistance in Leishmania. RSC Drug Discovery Series, 2017, , 371-386.	0.2	1
577	Proportion of Visceral Leishmaniasis and Human Immune Deficiency Virus Co- Infection among Clinically Confirmed Visceral Leishmaniasis Patients at the Endemic Foci of the Amhara National Regional State, North-West Ethiopia. American Journal of Biomedical and Life Sciences, 2014, 2, 1.	0.2	11
578	Magnitude and Associated Factors of Cutaneous Leishmaniasis; in Mekelle City, Ayder Referral Hospital, Tigray, Northern Ethiopia, 2014. Clinical Medicine Research, 2014, 3, 189.	0.0	8
579	Genome wide comparison of Ethiopian Leishmania donovani strains reveals differences potentially related to parasite survival. PLoS Genetics, 2018, 14, e1007133.	1.5	40
580	Early Clinical Manifestations Associated with Death from Visceral Leishmaniasis. PLoS Neglected Tropical Diseases, 2012, 6, e1511.	1.3	59
581	Risk Factors for Death from Visceral Leishmaniasis in an Urban Area of Brazil. PLoS Neglected Tropical Diseases, 2015, 9, e0003982.	1.3	32
582	Case Report: No Response to Liposomal Daunorubicin in a Patient with Drug-Resistant HIV-Associated Visceral Leishmaniasis. PLoS Neglected Tropical Diseases, 2015, 9, e0003983.	1.3	2
583	Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform. PLoS Neglected Tropical Diseases, 2017, 11, e0005781.	1.3	21
584	Prevalence and risk factors associated with Leishmania infection in Trang Province, southern Thailand. PLoS Neglected Tropical Diseases, 2017, 11, e0006095.	1.3	30
585	Tegumentary leishmaniasis and coinfections other than HIV. PLoS Neglected Tropical Diseases, 2018, 12, e0006125.	1.3	33
586	CYP5122A1, a Novel Cytochrome P450 Is Essential for Survival of Leishmania donovani. PLoS ONE, 2011, 6, e25273.	1.1	33
587	Leishmania donovani Infection Induces Anemia in Hamsters by Differentially Altering Erythropoiesis in Bone Marrow and Spleen. PLoS ONE, 2013, 8, e59509.	1.1	36
588	Epidemiology of Visceral Leishmaniasis in Algeria: An Update. PLoS ONE, 2014, 9, e99207.	1.1	21
589	A Multiplatform Metabolomic Approach to the Basis of Antimonial Action and Resistance in Leishmania infantum. PLoS ONE, 2015, 10, e0130675.	1.1	39
590	Immune Activation and Bacterial Translocation: A Link between Impaired Immune Recovery and Frequent Visceral Leishmaniasis Relapses in HIV-Infected Patients. PLoS ONE, 2016, 11, e0167512.	1.1	15
591	Development and external validation of a clinical prognostic score for death in visceral leishmaniasis patients in a high HIV co-infection burden area in Ethiopia. PLoS ONE, 2017, 12, e0178996.	1.1	5

#	Article	IF	Citations
592	Colonic leishmaniasis in a patient with HIV: a case report. Revista Espanola De Enfermedades Digestivas, 2016, 108, 838-840.	0.1	3
593	Prevalence of Hepatitis B, Hepatitis C, HIV and Malaria Co Infection among Patients Infected with Visceral Leishmaniasis in Gedarif, Eastern Sudan. Global Journal of Infectious Diseases and Clinical Research, 2016, 2, 021-024.	0.5	6
594	Cartagena: nuevo foco de leishmaniasis visceral urbana en Colombia.. Ciencia En Desarrollo, 2016, 7, 83-91.	0.1	5
595	Repositioning of HIV Aspartyl Peptidase Inhibitors for Combating the Neglected Human Pathogen Trypanosoma cruzi. Current Medicinal Chemistry, 2019, 26, 6590-6613.	1.2	5
596	Quinolines as Chemotherapeutic Agents for Leishmaniasis. Mini-Reviews in Medicinal Chemistry, 2013, 13, 730-743.	1.1	48
597	Outwitting an Old Neglected Nemesis: A Review on Leveraging Integrated Data-Driven Approaches to Aid in Unraveling of Leishmanicides of Therapeutic Potential. Current Topics in Medicinal Chemistry, 2020, 20, 349-366.	1.0	13
598	Biological Roles of Peptidases in Trypanosomatids~!2009-11-26~!2010-02-15~!2010-03-18~!. The Open Parasitology Journal, 2010, 4, 5-23.	1.7	13
599	First case of visceral Leishmaniosis/HIV coinfection in Nis - southeastern Serbia. Archives of Biological Sciences, 2012, 64, 1271-1276.	0.2	3
600	Multiple roles of proline transport and metabolism in trypanosomatids. Frontiers in Bioscience - Landmark, 2012, 17, 349.	3.0	38
601	Geographical distribution and epidemiological characteristics of visceral leishmaniasis in Bulgaria, 1988 to 2012. Eurosurveillance, 2013, 18, .	3.9	9
602	Geographical distribution and epidemiological characteristics of visceral leishmaniasis in Bulgaria, 1988 to 2012. Eurosurveillance, 2013, 18, 20531.	3.9	13
603	The burden of visceral leishmaniasis in Italy from 1982 to 2012: a retrospective analysis of the multi-annual epidemic that occurred from 1989 to 2009. Eurosurveillance, 2013, 18, 20535.	3.9	63
604	The role of indigenous phlebotomine sandflies and mammals in the spreading of leishmaniasis agents in the Mediterranean region. Eurosurveillance, 2013, 18, 20540.	3.9	86
605	Molecular typing of Leishmania infantum isolates from a leishmaniasis outbreak in Madrid, Spain, 2009 to 2012. Eurosurveillance, 2013, 18, 20545.	3.9	47
606	Spatial distribution and cluster analysis of a leishmaniasis outbreak in the south-western Madrid region, Spain, September 2009 to April 2013. Eurosurveillance, 2015, 20, 11-20.	3.9	24
607	Intestinal Parasitic Helminths of Rattus spp. in Caspian Sea Littoral, Iran. Journal of Medical Microbiology and Infectious Diseases, 2019, 7, 32-36.	0.1	1
608	Visceral leishmaniasis: a global overview. Journal of Global Health Science, 2020, 2, .	1.7	42
609	Parasitic infections in HIV infected individuals: Diagnostic & therapeutic challenges. Indian Journal of Medical Research, 2011, 134, 878.	0.4	57

#	Article	IF	Citations
610	Visceral leishmaniasis. Tropical Parasitology, 2015, 5, 83.	0.2	17
612	Public health aspects of visceral leishmaniasis in Montenegro. Open Journal of Clinical Diagnostics, 2013, 03, 195-201.	0.3	5
613	Human Competence to Transmit Leishmania infantum to Lutzomyia longipalpis and the Influence of Human Immunodeficiency Virus Infection. American Journal of Tropical Medicine and Hygiene, 2018, 98, 126-133.	0.6	32
614	Is Visceral Leishmaniasis Different in Immunocompromised Patients Without Human Immunodeficiency Virus? A Comparative, Multicenter Retrospective Cohort Analysis. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1127-1133.	0.6	13
615	Visceral Leishmaniasis and HIV Co-Infection in Northwest Ethiopia: Antiretroviral Treatment and Burden of Disease among Patients Enrolled in HIV Care. American Journal of Tropical Medicine and Hygiene, 2018, 98, 486-491.	0.6	10
616	Case Report: Diffuse Cutaneous Leishmaniasis by Leishmania infantum in a Patient Undergoing Immunosuppressive Therapy: Risk Status in an Endemic Mediterranean Area. American Journal of Tropical Medicine and Hygiene, 2018, 98, 1313-1316.	0.6	18
617	Visceral Leishmaniasis in Hospitalized HIV-Infected Patients in Pernambuco, Brazil. American Journal of Tropical Medicine and Hygiene, 2018, 99, 1541-1546.	0.6	12
618	Antigen Detection in Urine for Noninvasive Diagnosis and Treatment Monitoring of Visceral Leishmaniasis in Human Immunodeficiency Virus Coinfected Patients: An Exploratory Analysis from Ethiopia. American Journal of Tropical Medicine and Hygiene, 2018, 99, 957-966.	0.6	14
619	Secondary Prophylaxis with Liposomal Amphotericin B in a Patient with Mucosal Leishmaniasis Undergoing Immunobiological Therapy for Active Ankylosing Spondylitis. American Journal of Tropical Medicine and Hygiene, 2019, 101, 402-403.	0.6	2
620	Case Report: Confirmation by Metagenomic Sequencing of Visceral Leishmaniasis in an Immunosuppressed Returned Traveler. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1930-1933.	0.6	9
621	Case Report: Coinfection by Leishmania amazonensis and HIV in a Brazilian Diffuse Cutaneous Leishmaniasis Patient. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1076-1080.	0.6	9
622	Protease expression by microorganisms and its relevance to crucial physiological/pathological events. World Journal of Biological Chemistry, 2011, 2, 48.	1.7	26
623	CoinfecÃ§Ã£o Leishmania-HIV no Brasil: aspectos epidemiolÃ³gicos, clÃnicos e laboratoriais. Epidemiologia E Servicos De Saude: Revista Do Sistema Unico De Saude Do Brasil, 2011, 20, 519-526.	0.3	21
624	UrbanizaÃ§Ã£o da leishmaniose visceral: aspectos clÃnicos e epidemiolÃ³gicos em Aracaju, Sergipe, Brasil. Revista Brasileira De Medicina De FamÃlia E Comunidade, 2014, 9, 119-126.	0.1	3
625	Epidemiology and Ecology of Leishmaniasis. , 0, , .		16
626	The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis. ELife, 2016, 5, .	2.8	67
627	Vaccines against leishmaniasis: using controlled human infection models to accelerate development. Expert Review of Vaccines, 2021, 20, 1407-1418.	2.0	10
628	INTRODUCING MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES. Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009001.	0.5	0

#	Article	IF	Citations
629	Other protozoal infections. , 2010, , 823-841.		0
630	Blood and tissue protozoa. , 2010, , 1892-1901.		0
633	Leishmaniases. , 2011, , 73-98.		0
634	Chapter 6. Drugs for Kinetoplastid Diseases â€“ Current Situation and Challenges. RSC Drug Discovery Series, 2011, , 134-158.	0.2	0
638	The burden of visceral leishmaniasis in Italy from 1982 to 2012: a retrospective analysis of the multi-annual epidemic that occurred from 1989 to 2009. Eurosurveillance, 2013, 18, .	3.9	29
639	Visceral Leishmaniasis: Immune Mechanisms and New Insights in Vaccine Development and Control. Neglected Tropical Diseases, 2014, , 141-171.	0.4	0
640	â€œEmergingâ€•Neglected Tropical Diseases. , 0, , 273-285.		1
641	Do Not Forget Leishmaniasis. Journal of Microbiology & Experimentation, 2014, 1, .	0.1	0
642	Disseminated Cutaneous Leishmaniasis in a Man With Human Immunodeficiency Virus Infection. International Journal of Infection, 2015, 2, .	0.4	1
643	Leishmaniasis, malaria, and schistosomiasis concurrently in an 8-year-old boy. Journal of King Abdulaziz University, Islamic Economics, 2015, 36, 1012-1013.	0.5	0
644	Parasitic Infections in the Compromised Host. , 0, , 883-934.		0
645	Drug Resistance in Leishmaniasis. , 2017, , 1293-1304.		0
646	Leishmaniasis and HIV. , 2017, , 1-12.		0
647	DNA Topoisomerases as Promising Targets for Leishmania Chemotherapy. RSC Drug Discovery Series, 2017, , 348-370.	0.2	0
648	Skin Manifestations Associated with HIV/AIDS. , 2018, , 835-918.		0
649	Leishmaniasis and HIV. , 2018, , 1201-1211.		0
652	Investigating the dynamics of Leishmania antigen in the urine of patients with visceral leishmaniasis: a pilot study. F1000Research, 0, 7, 1514.	0.8	1
653	AUTOCHTHONOUS CASE OF CUTANEOUS LEISHMANIASIS IN HIV INFECTED PATIENT. HIV Infection and Immunosuppressive Disorders, 2019, 11, 75-80.	0.1	2

#	Article	IF	Citations
654	Integration of Bioinformatics and in vitro Analysis Reveal Anti-leishmanial Effects of Azithromycin and Nystatin. Current Bioinformatics, 2019, 14, 450-459.	0.7	3
655	Disease Ecology and Transmission. SpringerBriefs in Medical Earth Sciences, 2020, , 91-102.	0.3	0
656	Risk factors of inpatients mortality of visceral leishmaniasis, Khartoum State, Sudan. Journal of Global Infectious Diseases, 2020, 12, 135.	0.2	2
657	Low Knowledge and Attitude Towards Visceral Leishmaniasis Among Migrants and Seasonal Farm Workers in Northwest Ethiopia . Research and Reports in Tropical Medicine, 2020, Volume 11, 159-168.	2.8	3
658	Biomarkers of disease severity in patients with visceral leishmaniasis co-infected with HIV. Cytokine, 2022, 149, 155747.	1.4	3
659	Cutaneous manifestations of human immunodeficiency virus/acquired immunodeficiency syndrome: A comprehensive review. Journal of Dermatology & Dermatologic Surgery, 2020, 24, 66.	0.1	0
660	Treatment failure to sodium stibogluconate in cutaneous leishmaniasis: A challenge to infection control and disease elimination. PLoS ONE, 2021, 16, e0259009.	1.1	8
662	Leishmaniasis and HIV-infection â€“ an actual problem?. Jurnal Infektologii, 2020, 12, 72-77.	0.1	1
664	Serological Survey and Associated Risk Factors of Visceral Leish-maniasis in Qom Province, Central Iran. Iranian Journal of Public Health, 2014, 43, 50-5.	0.3	7
665	Endoparasites of Wild Rodents in Southeastern Iran. Journal of Arthropod-Borne Diseases, 2015, 9, 1-6.	0.9	15
666	One Health Approach Prospect for Integrated Control and Elimination of Visceral Leishmaniasis in Ethiopia: A Narrative Review Article. Iranian Journal of Parasitology, 2016, 11, 1-9.	0.6	24
667	Pediatric cutaneous leishmaniasis: A clinico-epidemiological study from North India. Indian Dermatology Online Journal, 2021, 12, 852.	0.2	1
668	Visceral Leishmaniasis: Asymptomatic Facts. , 0, , .		0
669	Aspectos epidemiolÃ³gicos da leishmaniose visceral no estado do PiauÃ, Brasil. Research, Society and Development, 2021, 10, e121101522690.	0.0	0
670	Leishmania donovani and HIV co-infection in vitro: Identification and characterization of main molecular players. Acta Tropica, 2022, 228, 106248.	0.9	3
671	Antileishmanial Drug Discovery and Development: Time to Reset the Model?. Microorganisms, 2021, 9, 2500.	1.6	32
673	The Knowns and Unknowns of the Efficacy and Safety of Neem Oil (Azadirachta Indica) Used as a Preventative Measure Against Leishmania Sand Fly Vectors (Diptera: Psychodidae). SSRN Electronic Journal, 0, , .	0.4	0
674	Classical and Modern Drug Treatments for Leishmaniasis. Topics in Medicinal Chemistry, 2021, , 1-21.	0.4	2

#	Article	IF	Citations
675	Impact of Genetic Diversity and Genome Plasticity of Leishmania spp. in Treatment and the Search for Novel Chemotherapeutic Targets. Frontiers in Cellular and Infection Microbiology, 2022, 12, 826287.	1.8	10
676	COINFECÃ‡ÃƒO LEISHMANIOSE VISCERAL E VÃRUS DA IMUNODEFICIÃŠNCIA HUMANA NO BRASIL: LEVANTAMENTO DE DADOS EPIDEMIOLÃ“GICOS. Recisatec, 2022, 2, e2178.	0.0	0
677	Leishmania and its relationships with bacteria. Future Microbiology, 2022, 17, 199-218.	1.0	1
678	Could combination chemotherapy be more effective than monotherapy in the treatment of visceral leishmaniasis? A systematic review of preclinical evidence. Parasitology, 2022, , 1-51.	0.7	2
679	AmBisome Monotherapy and Combination AmBisomeâ€“Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial. Clinical Infectious Diseases, 2022, 75, 1423-1432.	2.9	16
680	Leishmaniasis: Plants as a source of antileishmanial agents. Journal of Experimental Biology and Agricultural Sciences, 2022, 10, 227-247.	0.1	0
681	Diagnosis of Visceral Leishmaniasis in an Elimination Setting: A Validation Study of the Diagnostic Algorithm in India. Diagnostics, 2022, 12, 670.	1.3	4
682	New Insights on Drug-Resistant Clinical Isolates of Leishmania infantum-Infected Human Macrophages as Determined by Comparative Transcriptome Analyses. OMICS A Journal of Integrative Biology, 2022, 26, 165-177.	1.0	3
683	Transcriptomic Analysis in Human Macrophages Infected with Therapeutic Failure Clinical Isolates of Leishmania infantum. ACS Infectious Diseases, 2022, 8, 800-810.	1.8	9
684	Host-directed antileishmanial interventions: Harvesting unripe fruits to reach fruition. International Reviews of Immunology, 2023, 42, 217-236.	1.5	1
685	In Vitro Antileishmanial and Antischistosomal Activities of Anemonin Isolated from the Fresh Leaves of Ranunculus multifidus Forsk. Molecules, 2021, 26, 7473.	1.7	4
686	Protective and Pathogenic Immune Responses to Cutaneous Leishmaniasis. , 0, , .		0
690	Fever in HIV-infected patients: less frequent but still complex. Acta Clinica Belgica, 2012, 67, 276-81.	0.5	7
691	Tissue tropism: Is it an intrinsic characteristic of Leishmania species?. Acta Tropica, 2022, 232, 106512.	0.9	10
692	Tackling Drug Resistance and Other Causes of Treatment Failure in Leishmaniasis. Frontiers in Tropical Diseases, 2022, 3, .	0.5	17
693	Splenectomy in Patients with Visceral Leishmaniasis Resistant to Conventional Therapy and Secondary Prophylaxis: A Retrospective Cohort. American Journal of Tropical Medicine and Hygiene, 2022, 107, 342-348.	0.6	6
694	The kinetoplast in the diagnosis of visceral leishmaniasis. IDCases, 2022, 29, e01565.	0.4	0
695	Healed Lesions of Human Cutaneous Leishmaniasis Caused By Leishmania major Do Not Shelter Persistent Residual Parasites. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	2

#	Article	IF	Citations
696	Unwelcome prevalence of leishmaniasis with several other infectious diseases. International Immunopharmacology, 2022, 110, 109059.	1.7	8
697	Amphotericin B: A drug of choice for Visceral Leishmaniasis. Acta Tropica, 2022, 235, 106661.	0.9	23
698	Prevalence and determinants of asymptomatic Leishmania infection in HIV-infected individuals living within visceral leishmaniasis endemic areas of Bihar, India. PLoS Neglected Tropical Diseases, 2022, 16, e0010718.	1.3	3
699	Knowledge, Attitude, and Practices among HIV/Leishmaniasis Co-Infected Patients in Bihar, India. American Journal of Tropical Medicine and Hygiene, 2022, , .	0.6	0
700	HIV and Mediterranean Zoonoses: A Review of the Literature. Infectious Disease Reports, 2022, 14, 694-709.	1.5	3
701	Leishmaniasis epidemiology in endemic areas of metropolitan France and its overseas territories from 1998 to 2020. PLoS Neglected Tropical Diseases, 2022, 16, e0010745.	1.3	5
702	Trend of Visceral Leishmaniasis at Medicine Sans Frontierâ€™s Abdurafi Treatment Center, West Armachiho District, Ethiopia, 2009-2015, a retrospective descriptive analysis. Journal of Interventional Epidemiology and Public Health, 0, 5, .	0.3	0
704	The value of Metagenomic Next-Generation Sequencing in Leishmaniasis Diagnosis: A Case Series and Literature Review. Open Forum Infectious Diseases, 0, , .	0.4	1
705	Micro and nanotechnologies: The little formulations that could. Bioengineering and Translational Medicine, 2023, 8, .	3.9	9
706	Case Report: Autochthonous Disseminated Cutaneous, Mucocutaneous, and Visceral Leishmaniasis Caused by Leishmania martiniquensis in a Patient with HIV/AIDS from Northern Thailand and Literature Review. American Journal of Tropical Medicine and Hygiene, 2022, 107, 1196-1202.	0.6	8
707	Leishmania Species (Leishmaniasis). , 2023, , 1354-1364.e4.		1
708	Prevalence of visceral leishmaniasis among people with HIV: a systematic review and meta-analysis. European Journal of Clinical Microbiology and Infectious Diseases, 2023, 42, 1-12.	1.3	7
709	Review of the Clinical Presentation, Pathology, Diagnosis, and Treatment of Leishmaniasis. Laboratory Medicine, 2023, 54, 363-371.	0.8	13
710	Novel approaches to preventing phagosomal infections: timing is key. Trends in Immunology, 2022, , .	2.9	1
711	Hematological and Clinical Features Associated with Initial Poor Treatment Outcomes in Visceral Leishmaniasis Patients with and without HIV Coinfection in Gondar, Northwest Ethiopia. Tropical Medicine and Infectious Disease, 2023, 8, 36.	0.9	0
712	A Perspective on Mathematical Modeling and Machine Learning Models to Predict Visceral Leishmaniasis. , 2023, , 175-187.		0
713	Leishmaniasis: Tissue Tropism in Relation to the Species Diversity. , 2023, , 133-153.		3
714	Label-Free Mass Spectrometry Proteomics Reveals Different Pathways Modulated in THP-1 Cells Infected with Therapeutic Failure and Drug Resistance Leishmania infantum Clinical Isolates. ACS Infectious Diseases, 2023, 9, 470-485.	1.8	0

#	Article	IF	Citations
716	HIV pozitif hastalarda visseral leishmaniasis ve intestinal parazitlerin koenfeksiyonunun araÅŸtÄ±rÄ±lmasÄ±. KahramanmaraÅŸ SÃ¼tÃ§Ã¼ Ä°mam Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 0, , .	0.1	0
717	Leishmaniosis. , 2021, , 1179-1202.		0
718	Skin Manifestations Associated with HIV/AIDS. , 2023, , 1169-1258.		1
719	The cytokine/chemokine response in Leishmania/HIV infection and co-infection. Heliyon, 2023, 9, e15055.	1.4	10
720	Apigenin is a promising molecule for treatment of visceral leishmaniasis. Frontiers in Cellular and Infection Microbiology, 0, 13, .	1.8	4
721	The Role of the Leishmania infantum Infected Dogs as a Potential Reservoir Host for Toscana Virus in a Zoonotic Visceral Leishmaniasis Focus of Northern Tunisia. Viruses, 2023, 15, 1012.	1.5	1
729	Marine Bioactive Products as Potential Antileishmanial Therapeutics. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 225-249.	0.1	0
731	Clinical Features and Management of HIV/AIDS in Adults. , 2024, , 110-133.		0
750	KalaCORE: A Programme to Tackle Visceral Leishmaniasis in South Asia and East Africa (2014â€“2019). , 2023, , 19-41.		0